var title_f20_37_21072="Colonic angiodysplasia Endosc";
var content_f20_37_21072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colon angiodysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of T Edward Bynum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21072=[""].join("\n");
var outline_f20_37_21072=null;
var title_f20_37_21073="Dermoid cyst";
var content_f20_37_21073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermoid cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Slomovits, TL (Ed), Basic and clinical science courses section 8, American Academy of Ophthalmology, San Francisco 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21073=[""].join("\n");
var outline_f20_37_21073=null;
var title_f20_37_21074="Pulmonary histiocytosis X CT";
var content_f20_37_21074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution CT with thin section shows the cysts in pulmonary LCH, which vary markedly in size and may be larger than 10 mm. The cysts are bizarre in shape,&nbsp;often closely related to pulmonary arteries, and mimic bronchiectasis. Few nodules are present in this case.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21074=[""].join("\n");
var outline_f20_37_21074=null;
var title_f20_37_21075="WPW ablation site sinus rhythm";
var content_f20_37_21075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Intracardiac electrograms in Wolff-Parkinson-White",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three surface ECG leads (I, II, and V1) and intracardiac electrograms recorded from the proximal and distal high right atrium (HRA), the HIS bundle, an ablation (ABL) catheter, and the right ventricular apex (RVA). The surface ECGs show a widened QRS complex and short PR interval. The successful radiofrequency (RF) ablation site is where atrial (A) and ventricular (V) electrogram (EGM) are fused.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21075=[""].join("\n");
var outline_f20_37_21075=null;
var title_f20_37_21076="Muscularis propria invasion";
var content_f20_37_21076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Invasion of the muscularis propria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 152px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A-C, Urothelial carcinoma invading muscularis propria (detrusor muscle)(pT2).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21076=[""].join("\n");
var outline_f20_37_21076=null;
var title_f20_37_21077="Blood in fetal stomach";
var content_f20_37_21077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Intraamniotic bleeding and gastric pseudomass in fetus at 21 weeks' gestational age, 2 weeks after transplacental amniocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Transverse transabdominal sonogram shows echogenic particles floating in amniotic fluid (arrow) that were not present before amniocentesis. Until third trimester, echogenic particles in amniotic fluid should raise possibility of bleeding. Later in pregnancy, particles are most commonly the result of shed epithelial cells (vernix caseosa). (B) Transverse sonogram of fetal abdomen shows echogenic material (arrow) in stomach that results from fetus swallowing echogenic blood particles that resulted from recent amniocentesis. Gastric pseudomasses resolve on follow-up examination. To our knowledge, no gastric neoplasms have been reported on prenatal sonography.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trop I, Levine D. Hemorrage During Pregnancy: Sonography and MR Imaging. AJR Am J.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21077=[""].join("\n");
var outline_f20_37_21077=null;
var title_f20_37_21078="Types of frontonasal dysplasia";
var content_f20_37_21078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Types of frontonasal dysplasia due to mutations in cartilage-specific homeoproteins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALX: aristaless-like homeobox; FND: frontonasal dysplasia.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Uz E, Alanay Y, Aktas D, et al. Disruption of ALX1 causes extreme microphthalmia and severe facial clefting: Expanding the spectrum of autosomal-recessive ALX-related frontonasal dysplasia. Am J Hum Genet 2010; 86:789. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21078=[""].join("\n");
var outline_f20_37_21078=null;
var title_f20_37_21079="Irbesartan: Drug information";
var content_f20_37_21079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Irbesartan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/16/17669?source=see_link\">",
"    see \"Irbesartan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/5/26710?source=see_link\">",
"    see \"Irbesartan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avapro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avapro&reg;;",
"     </li>",
"     <li>",
"      CO Irbesartan;",
"     </li>",
"     <li>",
"      PMS-Irbesartan;",
"     </li>",
"     <li>",
"      ratio-Irbesartan;",
"     </li>",
"     <li>",
"      Sandoz-Irbesartan;",
"     </li>",
"     <li>",
"      Teva-Irbesartan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F184324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 150 mg once daily; patients may be titrated to 300 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Starting dose in volume-depleted patients should be 75 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nephropathy in patients with type 2 diabetes and hypertension:",
"     </b>",
"     Oral: Target dose: 300 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F184343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/5/26710?source=see_link\">",
"      see \"Irbesartan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;6 years: Safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;6-12 years: Initial: 75 mg once daily; may be titrated to a maximum of 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     13-16 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aortic-root dilation with Marfan&rsquo;s syndrome (unlabeled use):",
"     </b>",
"     Children 14 months to 16 years: Initial: 1.4 mg/kg/day; can be increased to a maximum of 2 mg/kg/day (not to exceed adult maximum of 300 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F184325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F184326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary with mild to severe impairment unless the patient is also volume depleted.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 75 mg, 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avapro&reg;: 75 mg, 150 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension alone or in combination with other antihypertensives; treatment of diabetic nephropathy in patients with type 2 diabetes mellitus (noninsulin dependent, NIDDM) and hypertension",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6154963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To slow the rate of progression of aortic-root dilation in pediatric patients with Marfan&rsquo;s syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F184364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Avapro&reg; may be confused with Anaprox&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F184354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unless otherwise indicated, percentage of incidence is reported for patients with hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Endocrine &amp; metabolic: Hyperkalemia (19%, diabetic nephropathy; rarely seen in HTN)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (5%, diabetic nephropathy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (4%), dizziness (10%, diabetic nephropathy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (3%), dyspepsia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (9%), cough (2.8% versus 2.7% in placebo)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports (Limited to important or life-threatening): Anemia (case report; Simonetti, 2007), angina, angioedema, arrhythmia, cardiopulmonary arrest, conjunctivitis, depression, dyspnea, ecchymosis, epistaxis, gout, heart failure, hepatitis, hypotension, jaundice, libido decreased, MI, orthostatic hypotension, paresthesia, renal failure, renal function impaired, sexual dysfunction, stroke, thrombocytopenia, transaminases increased, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to irbesartan or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F184285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with irbesartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use irbesartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution with pre-existing renal insufficiency, and severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F184350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (moderate), CYP2C9 (moderate), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Irbesartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F184316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Dong quai has estrogenic activity. Some herbal medications may worsen hypertension (eg, ephedra); garlic may have additional antihypertensive effects. Management: Avoid dong quai if using for hypertension. Avoid ephedra, yohimbe, ginseng, and garlic.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F184303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     The use of drugs which act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Use is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F184329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F184304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F184302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Avapro Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (30): $97.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (90): $307.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (90): $369.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Irbesartan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (30): $87.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $92.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $110.78",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13361461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Electrolytes, serum creatinine, BUN, urinalysis",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F184305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Approvel (DE);",
"     </li>",
"     <li>",
"      Aprovel (AR, AT, BB, BE, BO, BR, BS, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IT, JM, KP, MT, MX, MY, NI, NL, NO, PA, PE, PH, PK, PL, PR, PT, PY, RU, SE, SG, SK, SV, TH, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Aprtan (KP);",
"     </li>",
"     <li>",
"      Avapro (AR, AU, BM, BR, BZ, GY, MX, SR);",
"     </li>",
"     <li>",
"      Bezart (PH);",
"     </li>",
"     <li>",
"      Elzar (ID);",
"     </li>",
"     <li>",
"      Fritens (ID);",
"     </li>",
"     <li>",
"      Ibefro (KP);",
"     </li>",
"     <li>",
"      Ibera (KP);",
"     </li>",
"     <li>",
"      Ibetan (KP);",
"     </li>",
"     <li>",
"      Irbec (BG);",
"     </li>",
"     <li>",
"      Irbenox (TH);",
"     </li>",
"     <li>",
"      Irbesel (PE);",
"     </li>",
"     <li>",
"      Irbetan (TW);",
"     </li>",
"     <li>",
"      Irbett (EC);",
"     </li>",
"     <li>",
"      Irebeprex (CO);",
"     </li>",
"     <li>",
"      Iretensa (ID);",
"     </li>",
"     <li>",
"      Irovel (IN);",
"     </li>",
"     <li>",
"      Irtan (ID);",
"     </li>",
"     <li>",
"      Irvebal (ID);",
"     </li>",
"     <li>",
"      Irvell (ID);",
"     </li>",
"     <li>",
"      Izatan (KP);",
"     </li>",
"     <li>",
"      Karvea (AT, AU, ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F184284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Irbesartan is an angiotensin receptor antagonist. Angiotensin II acts as a vasoconstrictor. In addition to causing direct vasoconstriction, angiotensin II also stimulates the release of aldosterone. Once aldosterone is released, sodium as well as water are reabsorbed. The end result is an elevation in blood pressure. Irbesartan binds to the AT1 angiotensin II receptor. This binding prevents angiotensin II from binding to the receptor thereby blocking the vasoconstriction and the aldosterone secreting effects of angiotensin II.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F184299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &gt;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 53-93 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, primarily CYP2C9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 60% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 11-15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (80%); urine (20%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brooke BS, Habashi JP, Judge DP, et al, &ldquo;Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(26):2787-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/18579813/pubmed\" id=\"18579813\" target=\"_blank\">",
"        18579813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K, Kjekshus J, et al, &ldquo;Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, &ldquo;Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114 (2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(2):203.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, &ldquo;Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      ,  2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simonetti GD, Bianchetti MG, Konrad M, et al, \"Severe Anemia Caused by the Angiotensin Receptor Blocker Irbesartan After Renal Transplantation,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2007, 22(5):756-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/17216246/pubmed\" id=\"17216246\" target=\"_blank\">",
"        17216246",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/37/21079/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8640 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.104-2CE9AB38EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21079=[""].join("\n");
var outline_f20_37_21079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708952\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184320\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184321\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184356\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184324\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184343\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184325\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184326\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160031\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184295\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184281\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184296\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6154963\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184364\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184354\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184300\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184285\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184350\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184290\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184316\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184292\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184303\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184329\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184304\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184302\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13361461\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184305\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184284\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184299\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8640\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8640|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/16/17669?source=related_link\">",
"      Irbesartan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/5/26710?source=related_link\">",
"      Irbesartan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_37_21080="Sinus arrhythmia tutorial";
var content_f20_37_21080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1122px;\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Sinus arrhythmia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 122px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sinus arrhythmia is present when there is a sinus rhythm with variability in the cycle lengths between successive P waves. This rhythm strip reveals a gradual increase and decrease in the heart rate with the respiratory cycle; the heart rate increases with inspiration and decreases with expiration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21080=[""].join("\n");
var outline_f20_37_21080=null;
var title_f20_37_21081="Use of red blood cells for transfusion";
var content_f20_37_21081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of red blood cells for transfusion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/37/21081/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/37/21081/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/37/21081/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/37/21081/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/37/21081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/37/21081/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/37/21081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red blood cell (RBC) transfusions are given to raise the hematocrit level in patients with anemia or to replace losses after acute bleeding episodes. Storage of red cells has been enhanced by the development of preservative solutions; in addition, several types of components are available for use in selected circumstances to minimize complications. This topic review will discuss the storage and use of these various preparations.",
"   </p>",
"   <p>",
"    Complications of large volume transfusion such as dilution of clotting proteins, hypothermia, and complications of citrate infusion (a fall in the ionized calcium concentration and metabolic alkalosis) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=see_link\">",
"     \"Administration and complications of red cell transfusion in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link\">",
"     \"Transfusion-related acute lung injury (TRALI)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link\">",
"     \"Transfusion transmitted bacterial infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link\">",
"     \"Transfusion reactions caused by chemical and physical agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications for RBC transfusion are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=see_link\">",
"     \"Indications for red blood cell transfusion in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link\">",
"     \"Red blood cell transfusions in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COLLECTION AND STORAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood collections are routinely separated into various components (ie, red cells, plasma, cryoprecipitate, platelets) and the RBC are stored for up to 42 days. These processes have markedly enhanced our ability to meet transfusion requirements and are due to two important developments, namely preservative solutions that allow for a long shelf-life of the red cells, and storage bags that permit separation of blood components and maintain sterility and viability of the contained red cells. These are discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=see_link\">",
"     \"Preparation of blood components\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preservative solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it was recognized since 1916 that red cells could be stored for brief periods of time in a citrate-glucose solution, it was not until the 1930s that blood was transfused after storage and not until 1937 that the first blood \"bank\" was established at Cook County Hospital in Chicago [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/1\">",
"     1",
"    </a>",
"    ]. In the early 1940s, a major breakthrough came with the development of the first effective anticoagulant-preservative solution (A-P) ACD (acid citrate dextrose) which allowed blood to be stored for up to 21 days.",
"   </p>",
"   <p>",
"    During the ensuing years, significant progress has been made in the development of other A-P solutions, such as citrate phosphate dextrose (CPD) for 21-day storage, CPD-adenine for 35-day storage, and the current generation of additive solutions that permit storage for 42 days. Newer solutions to allow for even longer storage times are currently under study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. As the shelf-life of blood has been extended, the loss of collections through outdating has been progressively reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Storage bags",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of equal importance was the development of plastic storage bags that became generally available around 1960 and permitted the separation of collected blood into red cells, plasma, platelets, and cryoprecipitate in a closed and therefore sterile environment.",
"   </p>",
"   <p>",
"    Today, whole blood collections are routinely separated into an average of 1.7 components (including fresh frozen plasma, platelets, and cryoprecipitate); this provides the ability to support the transfusion needs of multiple patients from a single donation and has led to the virtual disappearance of the availability of whole blood from blood banks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHOICE OF COMPONENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a decision to transfuse has been made (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    ), the choice is between red cells (RBC) or whole blood (WB) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/5\">",
"     5",
"    </a>",
"    ]. The major difference between these two blood components is the volume of plasma present in the unit of blood.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When CPD-A is the anticoagulant used (35 day storage), the hematocrit of the unit of RBCs is approximately 65 percent, since all but about 50 mL of the supernatant plasma is removed, resulting in a volume of 250 mL.",
"     </li>",
"     <li>",
"      When an additive solution system is used (42 day storage), virtually all of the plasma is removed and then replaced with approximately 100 mL of storage solution resulting in a PCV of approximately 40 percent and a volume of 310 mL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with chronic anemia should be transfused with RBC since volume replacement is not required. Furthermore, since the patient already has an expanded blood volume to compensate for the anemia, circulatory overload may be a risk if plasma is also given. Whole blood should be considered only when treating an adult who has bled acutely and massively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC CHANGES WITH STORAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of changes that occur during red cell storage that may have a significant impact on the recipient and may require that transfusion practices be modified to avoid potential complications. These include decreased viability, deformability, 2,3 bisphosphoglycerate, ATP and glutathione [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/6\">",
"     6",
"    </a>",
"    ], and nitric oxide; and potassium leakage. These issues are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Red cell viability and recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;When stored RBC are transfused, some of the cells are removed from the circulation in the first few hours while the rest survive normally; as the storage time of the RBC unit increases, more and more cells are removed by physiologic mechanisms immediately after transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/7\">",
"     7",
"    </a>",
"    ]. This loss of viability is also highly dependent upon the A-P solution used, donor-to-donor variation, leukoreduction, the amount of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    in storage solutions, and storage hematocrit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One criterion for FDA licensing of A-P solutions is to measure the 24-hour recovery of autologous radiolabeled red cells in normal subjects after different intervals of storage. The recovery threshold for the percentage of circulating red cells 24 hours following infusion is currently set at 75 percent, with some ongoing discussion about the degree of statistical variation that is allowable [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     2,3 BPG concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cell 2,3 bisphosphoglycerate (2,3-BPG, previously called 2,3 diphosphoglycerate, 2,3- DPG) levels affect the ability of RBC to deliver oxygen to the tissues by altering the position of the oxyhemoglobin dissociation curve. After five to six weeks of storage, levels in the RBC progressively fall toward 10 percent of normal. As a result, the oxyhemoglobin dissociation curve progressively shifts to the left, resulting in reduced oxygen release by hemoglobin at any given tissue pO2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link&amp;anchor=H9#H9\">",
"     \"Structure and function of normal human hemoglobins\", section on '2,3-bisphosphoglycerate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is uncertain whether this abnormality is physiologically important, even in critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/12\">",
"     12",
"    </a>",
"    ]. Even if it were, the red cell 2,3 BPG concentrations increase to normal within 6 to 24 hours of transfusion, resulting in normalization of oxygen release [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Potassium leakage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma potassium concentrations in stored blood increase approximately 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per day due to passive leakage out of the red cells. Potassium is not actively transported back into the RBC because membrane ATPase is inhibited at 1 to 6&deg;C, the temperature range employed for storage of red cells. The potassium concentration peaks at about 30 to 50",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in whole blood (90",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in packed RBC products), and as high as 70",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 28-day-old irradiated blood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13954561\">",
"     'Irradiated red cells'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Loss of one unit of blood through bleeding would result in the loss of 1.5 meq of potassium (5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    x 0.3 L of plasma); transfusion of one unit of whole blood or RBC would be expected to provide approximately 10 meq of potassium, leading to a net gain of 8.5 meq [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/15\">",
"     15",
"    </a>",
"    ]. There is usually no increase in the serum potassium concentration, since the excess potassium moves into cells and some is excreted in the urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13954554\">",
"    <span class=\"h3\">",
"     Hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are modestly increased levels of extracellular potassium in red cell preparations in the latter days of their allotted storage time, severe hyperkalemia from transfusion of properly collected and stored (ie, not hemolyzed) red blood cells is rarely seen in adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/17\">",
"     17",
"    </a>",
"    ]. Risk factors for transfusion-related hyperkalemia include the rate and volume of the transfusion, the use of a central venous infusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pressure pumping, the use of irradiated blood, and the age of the blood infused [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three clinical settings in which there is an increased risk of transfusion-related hyperkalemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Severe trauma",
"      </strong>",
"      &mdash; Hyperkalemia is a common occurrence in patients with severe trauma, with a prevalence of 29 percent in massively traumatized patients at a United States military combat support hospital in Iraq [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/19\">",
"       19",
"      </a>",
"      ].&nbsp;Although blood product transfusion plays an important role, other risk factors include tissue breakdown with the release of cellular potassium into the extracellular fluid, a low cardiac output which impairs renal function, and hypocalcemia which can increase the severity of the manifestations of hyperkalemia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link&amp;anchor=H14#H14\">",
"       \"Massive blood transfusion\", section on 'Prevention of hyperkalemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment and prevention of hyperkalemia in adults\", section on 'Calcium'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Impaired renal function",
"      </strong>",
"      &mdash; Renal excretion of the potassium load provided in blood transfusions limits the elevation in serum potassium. This protective effect is diminished in patients with moderate to severely impaired renal function. Such patients may require modifications in transfusion practices, such as the use of fresher or washed red cells. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Washed red cells'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link&amp;anchor=H270425989#H270425989\">",
"       \"Causes and evaluation of hyperkalemia in adults\", section on 'Acute and chronic kidney disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Infants and newborns",
"      </strong>",
"      &mdash; Infants and newborns are another group at increased risk for transfusion-related hyperkalemia due to the low rate of urinary excretion of a potassium load. Protective measures include the use of fresher red cells, washed red cells,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a bedside potassium adsorption filter [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Washed red cells'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      In newborn infants, blood that is less than seven days old is generally used in order to avoid this problem, although there is a trade-off between obtaining fresh blood and minimizing the number of potential blood donors for a single neonate [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27591?source=see_link&amp;anchor=H21#H21\">",
"       \"Fluid and electrolyte therapy in newborns\", section on 'Hyperkalemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=see_link&amp;anchor=H16#H16\">",
"       \"Administration and complications of red cell transfusion in infants and children\", section on 'Metabolic toxicity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13954561\">",
"    <span class=\"h3\">",
"     Irradiated red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cells that have been irradiated to prevent graft-versus-host disease leak more potassium than non-irradiated products. As a result, their shelf life is reduced to 28 days. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Potassium leakage'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link&amp;anchor=H8#H8\">",
"     \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Irradiated red cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of irradiated red cells, especially if they have been stored for some days after irradiation, may result in significant degrees of hyperkalemia in some pediatric settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link&amp;anchor=H10#H10\">",
"     \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ammonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma ammonia concentrations progressively increase in stored blood, approaching 900",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    after five to six weeks. It has been suggested that this amount of ammonia may make it undesirable to transfuse large numbers of stored units of blood to a patient with high ammonia levels, and that saline-washed red cells should be used instead [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endogenous nitric oxide (NO) was originally named endothelium-derived relaxing factor. It is a naturally occurring vasodilator that works with other molecules to determine vascular resistance. S-nitrosohemoglobin (SNO-Hb) is formed in human red blood cells when a nitric oxide equivalent binds to hemoglobin. Red cells subsequently release limited fluxes of vasodilator SNO equivalents in proportion to hemoglobin desaturation, matching regional blood flow with metabolic demand [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38982?source=see_link&amp;anchor=H3#H3\">",
"     \"Inhaled nitric oxide in adults with pulmonary hypertension\", section on 'Physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, red cell SNO-Hb was serially assayed in blood collected from 15 normal volunteers and processed and stored according to AABB standards [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/26\">",
"     26",
"    </a>",
"    ]. Red cell SNO-Hb decreased by 82 percent three hours after processing, and remained low over a 42-day storage period. Red cell-dependent vasoactivity, as measured in rabbit aortic rings at low pO2 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/23,25\">",
"     23,25",
"    </a>",
"    ], was significantly depressed at three hours in both control and processed blood, with some recovery after about four days in storage. In separate experiments in dogs, stored blood replenished with nitric oxide had red-cell vasoactivity similar to that of fresh blood.",
"   </p>",
"   <p>",
"    The clinical significance of these changes is not known at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical relevance of storage time",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no as yet completed prospective randomized controlled studies examining the effect of storage duration of transfused red cells on morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/28\">",
"     28",
"    </a>",
"    ]. However, a number of retrospective studies, a few prospective non-randomized studies, reviews and meta-analyses (summarized in references [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]), and a study in experimental animals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/31\">",
"     31",
"    </a>",
"    ] have concluded that increased storage age of transfused blood is [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/31-46\">",
"     31-46",
"    </a>",
"    ], or is not [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/29,39,42,47-53\">",
"     29,39,42,47-53",
"    </a>",
"    ], an independent risk factor for a number of adverse endpoints, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Post-injury multiple organ failure [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/33,45,52\">",
"       33,45,52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Post-injury mortality, renal dysfunction, and pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/31,42\">",
"       31,42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Rate of infection after severe injury [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/38,52\">",
"       38,52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mortality in patients admitted to the ICU with sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pneumonia following coronary artery bypass graft surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Morbidity and mortality following cardiac surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/36,39,40,46-48\">",
"       36,39,40,46-48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mortality in hospitalized patients with cardiovascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Disease recurrence after colorectal cancer surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neurocognitive deficits with acute anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced cerebral oxygenation after traumatic brain injury [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced tissue oxygenation in critically ill trauma patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pulmonary function in mechanically ventilated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/53\">",
"       53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreased nitric oxide bioavailability resulting in vasoconstriction and hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/31,55\">",
"       31,55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Enhanced in vitro proliferation of a pathogenic strain of E. coli [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential importance of the duration of red cell storage was illustrated in a retrospective study of 6000 patients undergoing cardiac surgery who received red cell transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/40\">",
"     40",
"    </a>",
"    ]. The use of blood stored for more than 14 days was associated with a significant increase in mortality both in-hospital (2.8 versus 1.7 percent with units stored for 14 days or less) and at one year (11.0 versus 7.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such retrospective studies are limited in their ability to demonstrate causality. Furthermore, other studies have not demonstrated an independent effect of red cell storage time on outcomes after coronary artery bypass graft surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/39,47,48\">",
"     39,47,48",
"    </a>",
"    ] and any potential benefits of using blood stored for two weeks or less must be weighed against the difficulty of maintaining the blood supply if only fresher units were used for transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, available studies do not present compelling enough evidence to alter transfusion practice toward the selective use of fresher cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/27,47,49,57\">",
"     27,47,49,57",
"    </a>",
"    ], or to answer the paired questions as to whether or not \"fresh blood is better\" and \"older blood is potentially harmful\" [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. The interested reader is referred to a mini-symposium on RBC storage and a separate review, which discuss many of the above issues [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The ongoing Red Cell Storage Duration Study (RECESS) will compare the effects of transfusing red cell units stored &le;10 days versus those stored &ge;21 days in patients undergoing complex cardiac surgery to determine their effects on clinical outcomes and mortality risk",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00991341?term=RECESS&amp;rank=1\">",
"     RECESS STUDY NCT00991341",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The immunosuppressive activity of allogeneic blood transfusion of any age is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H6#H6\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Immunosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SPECIALIZED RBC COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of ways to treat red cells in an attempt to minimize complications that occur in certain patient populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Leukoreduced red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several complications of RBC transfusion appear to be due to contamination with leukocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HLA alloimmunization against class I antigens does not appear to occur if the red cell preparation contains less than 10",
"      <sup>",
"       6",
"      </sup>",
"      leukocytes. There are now numerous commercially available filters (either integrated into blood collection sets or available for sterile connection after the whole blood unit is collected) that accomplish this degree of leukocyte removal.",
"     </li>",
"     <li>",
"      Some patients experience febrile transfusion reactions that are due to white cell contamination of the red cell concentrate rather than RBC alloimmunization. In this setting, the time at which the red cells are filtered is important. The red cells should be filtered as close to the collection time as possible, in order to remove intact leukocytes that would otherwise fragment over time, releasing cytokines that are responsible for the febrile response. This requires that leukoreduction filters be used in the blood collecting facility rather than in the hospital blood bank or at the bedside.",
"     </li>",
"     <li>",
"      Leukoreduction is an effective method to prevent (or at a minimum, markedly reduce) the risk of transfusion-transmitted cytomegalovirus infection. CMV resides in the leukocytes and is removed during leukoreduction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H11#H11\">",
"       \"Leukoreduction to prevent complications of blood transfusion\", section on 'Viral diseases'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ideally, leukoreduction to eliminate leukocyte debris and leukocyte-generated cytokines would be performed on all cellular components intended for transfusion. This policy of universal leukoreduction is standard practice in many developed countries, while a minority of other countries (including the United States) have yet to require universal leukoreduction as the official standard of care. Approximately 85 percent of red blood cells are pre-storage leukoreduced in the United States, and more than 80 percent of institutions in the United States have implemented universal leukoreduction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/64\">",
"     64",
"    </a>",
"    ]. If selected leukoreduction is used, patients who should receive leukoreduced products include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronically transfused patients",
"     </li>",
"     <li>",
"      Patients undergoing cardiac surgery",
"     </li>",
"     <li>",
"      All potential recipients of solid organ or hematopoietic cell transplants",
"     </li>",
"     <li>",
"      Patients with solid organ or hematopoietic cell transplants",
"     </li>",
"     <li>",
"      Patients with previous febrile nonhemolytic transfusion reactions",
"     </li>",
"     <li>",
"      CMV seronegative at-risk patients for whom seronegative components are not available",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Leukoreduction adds only a small additional cost to each unit of RBC. If cost considerations allow, leukoreduction of RBC for all patients would be ideal.",
"   </p>",
"   <p>",
"    Technical aspects of leukoreduction, as well as other potential adverse effects of transfused white blood cells, such as immunosuppression and tumor recurrence, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Irradiated red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to avoid the occurrence of graft-versus-host disease (GVHD) in patients who have immune deficiency states, transfused red cells must be subjected to irradiation with at least 25 Gy to prevent the donor T lymphocytes from dividing in the recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/65\">",
"     65",
"    </a>",
"    ]. Irradiation to prevent GVHD is also recommended for red cells collected from relatives entered in directed donation programs. It has become more generally accepted that irradiated red cells should also be used for transfusion in cancer patients immunosuppressed by large doses of chemotherapy. Guidelines on which patients should receive irradiated blood products can be found elsewhere (",
"    <a class=\"graphic graphic_table graphicRef81912 \" href=\"UTD.htm?10/37/10844\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link&amp;anchor=H3#H3\">",
"     \"Transfusion-associated graft-versus-host disease\", section on 'Immunodeficient states'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link&amp;anchor=H8#H8\">",
"     \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Irradiated red cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The levels of irradiation necessary to inactivate lymphocytes also induce a lesion in the red cell membrane. This can lead to reduced red cell viability and a leakage of potassium, decreasing the shelf-life of irradiated RBC products to no more than 28 days of total storage time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/67-71\">",
"     67-71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link&amp;anchor=H8#H8\">",
"     \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Irradiated red cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Washed red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to prevent or eliminate complications associated with infusion of proteins present in the small amount of residual plasma in red cell concentrates, the unit of blood can be washed immediately before infusion. This approach is indicated for the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe or recurrent allergic reactions (eg, hives) associated with red cell transfusion",
"     </li>",
"     <li>",
"      Certain patients with IgA deficiency when IgA deficient donors are not available (although frozen deglycerolized red cells may be the component of choice; see below); patients with IgA deficiency may have circulating anti-IgA antibodies that react with IgA in the donor plasma",
"     </li>",
"     <li>",
"      In the rare patient with a complement-dependent autoimmune hemolytic anemia to prevent complement infusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Washing of red blood cells prior to infusion can also be used to reduce the amount of transfused potassium for patients who are at risk for developing hyperkalemia. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Potassium leakage'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Frozen deglycerolized red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, red blood cells frozen in 40 percent glycerol are approved by the FDA and the AABB for storage at -80&ordm;C for up to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/72\">",
"     72",
"    </a>",
"    ]. The use of this product was evaluated in a prospective, randomized trial of 57 stable trauma patients who required blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/73\">",
"     73",
"    </a>",
"    ]. Compared with refrigerated RBC, frozen deglycerolized cells were noninferior with respect to increasing hematocrit, effects on thromboelastography parameters, and clinical outcomes.",
"   </p>",
"   <p>",
"    The need to subject red cells to glycerolization and freezing, and the time and effort required for thawing and washing immediately before infusion increases cost and delays transfusion. Thus, frozen deglycerolized red cells have a limited number of indications. These include use in patients with IgA deficiency for whom IgA negative donors do not exist (since this process removes more plasma than simply washing the RBC), as well as the long-term storage of \"rare\" RBC units of blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Elimination of blood group antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enzymatic conversion of A, B, and AB red cells to group O has been achieved in vitro via the use of exoglycosidases derived from bacterial sources [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/74\">",
"     74",
"    </a>",
"    ]. This enzymatic conversion (ECO) technique, if proven to be safe and effective, has the potential to simplify blood transfusion by eliminating the risk for ABO-incompatible transfusion errors and creating a more universal blood inventory [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link&amp;anchor=H2#H2\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'ABO (ABH) blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21832187\">",
"    <span class=\"h2\">",
"     Ex vivo generation of red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited numbers of viable red cells can be generated ex vivo in culture systems from CD34+ hematopoietic stem cells. In a proof-of-principle study, such red cells were fully functional in terms of their deformability, enzyme content, capacity of their hemoglobin to release oxygen, and expression of blood group antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/76\">",
"     76",
"    </a>",
"    ]. When 10",
"    <sup>",
"     10",
"    </sup>",
"    of these cells were injected intravenously into one human subject, in vivo survival approximated that seen for normal donor red cells.",
"   </p>",
"   <p>",
"    Although this is an exciting first step, there are formidable barriers to the large-scale production of such red cells for therapeutic transfusion purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5049651\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of red blood cell administration include attention to the following [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consent &ndash; Evidence that informed consent for blood component transfusion was obtained from the intended recipient should be verified before all non-emergent administration of blood components. According to AABB standards, elements of consent should include: a description of the risks, benefits, and treatment alternatives; the opportunity for the intended recipient to ask questions; and the right of the patient to accept or refuse transfusion.",
"     </li>",
"     <li>",
"      Venous access (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6361?source=see_link\">",
"       \"Peripheral venous access in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link\">",
"       \"Overview of central venous access\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patient identification to ensure that the intended transfusion is given to the intended recipient (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H7#H7\">",
"       \"Immunologic blood transfusion reactions\", section on 'Acute hemolytic reactions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=see_link&amp;anchor=H15#H15\">",
"       \"Compatibility testing\", section on 'Release of blood in emergency situations when compatibility testing has not been completed'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Premedication &ndash; The possible use of premedication (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antihistamines) to prevent febrile nonhemolytic or allergic transfusion reactions is not supported by data; this issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H5#H5\">",
"       \"Immunologic blood transfusion reactions\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Filters &ndash; All units must be transfused through a standard 170- to 200-micron filter (contained as an integral part of a standard infusion set) designed to remove clots and aggregates.",
"     </li>",
"     <li>",
"      Compatible fluids &ndash; No other intravenous solutions or medications except 0.9 percent sodium chloride for injection, ABO compatible plasma, or albumin should be administered through the same tubing concurrently with the red blood cells. Dextrose solutions can cause red cells to swell osmotically and lyse, and lactated Ringer&rsquo;s solutions contain levels of calcium that may overcome the buffering capacity of the anticoagulant in the storage solution, causing the blood to clot. When administering red blood cells through central venous catheters with multiple lumens, other lumens can be used concurrently for infusion of medications. However, caution should be exercised if the medication is associated with known adverse effects or if it is being administered to the patient for the first time. Medications and fluids can also be administered through the same lumen as a red blood cell transfusion; in this scenario, the lumen should be flushed with normal saline both before and after medication infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21081/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infusion rate &ndash; Suggested rates for adults are 1 to 2 mL per minute (60 to 120 mL per hour) for the first 15 minutes and then as rapidly as tolerated; the complete infusion should not exceed four hours. However, slower rates of infusion (possibly combined with administration of a smaller unit to comply with the four-hour infusion requirement)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the administration of diuretics may be indicated for patients who are predisposed to circulatory overload. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link&amp;anchor=H2#H2\">",
"       \"Transfusion reactions caused by chemical and physical agents\", section on 'Transfusional volume overload (TACO)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The administration and complications of red cell transfusion in infants and children is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=see_link&amp;anchor=H2#H2\">",
"       \"Administration and complications of red cell transfusion in infants and children\", section on 'Administration'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22828480\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Red blood cell (RBC) transfusions are given to raise the hematocrit level in patients with anemia or to replace losses after acute bleeding episodes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"       \"Indications for red cell transfusion in the adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A patient with chronic anemia should be transfused with packed RBC rather than whole blood, since volume replacement is not required. Whole blood should be considered only when dealing with an adult who has bled acutely and massively. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Choice of component'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"       \"Massive blood transfusion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The current generation of additive solutions and blood",
"      <span class=\"nowrap\">",
"       collection/storage",
"      </span>",
"      bags permit storage of RBC for 42 days. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Collection and storage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of adverse changes occur with RBC storage at refrigerator temperatures (eg, decreases in 2,3-BPG and nitric oxide, increases in cell-free potassium and ammonia). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physiologic changes with storage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical relevance of longer versus shorter storage time is not clear at this time. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical relevance of storage time'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Available RBC preparations include whole blood, packed RBC, irradiated RBC, leukoreduced RBC, washed RBC, and frozen deglycerolized RBC. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Specialized RBC components'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The administration of the blood should include consent, identification of the proper recipient, appropriate venous access, attention to the infusion rate, and avoidance of the concurrent administration of incompatible solutions. (See",
"      <a class=\"local\" href=\"#H5049651\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/1\">",
"      Collins JA. Problems associated with the massive transfusion of stored blood. Surgery 1974; 75:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/2\">",
"      Hess JR, Rugg N, Knapp AD, et al. Successful storage of RBCs for 10 weeks in a new additive solution. Transfusion 2000; 40:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/3\">",
"      Hess JR, Hill HR, Oliver CK, et al. Twelve-week RBC storage. Transfusion 2003; 43:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/4\">",
"      H&ouml;gman CF, Meryman HT. Red blood cells intended for transfusion: quality criteria revisited. Transfusion 2006; 46:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/5\">",
"      Counts RB, Haisch C, Simon TL, et al. Hemostasis in massively transfused trauma patients. Ann Surg 1979; 190:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/6\">",
"      Whillier S, Raftos JE, Sparrow RL, Kuchel PW. The effects of long-term storage of human red blood cells on the glutathione synthesis rate and steady-state concentration. Transfusion 2011; 51:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/7\">",
"      Luten M, Roerdinkholder-Stoelwinder B, Schaap NP, et al. Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods. Transfusion 2008; 48:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/8\">",
"      Hess JR, Sparrow RL, van der Meer PF, et al. Red blood cell hemolysis during blood bank storage: using national quality management data to answer basic scientific questions. Transfusion 2009; 49:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/9\">",
"      Heaton WM. Red blood cell hemolysis: an old standard in changing times. Transfusion 2009; 49:2551.",
"     </a>",
"    </li>",
"    <li>",
"     Council of Europe. Guide to the preparation, use and quality assurance of blood components. Recommentation R (95) 15, 11th ed, Council of Europe Publishing, Strasbourg 2005. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/11\">",
"      Dumont LJ, AuBuchon JP. Evaluation of proposed FDA criteria for the evaluation of radiolabeled red cell recovery trials. Transfusion 2008; 48:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/12\">",
"      Walsh TS, McArdle F, McLellan SA, et al. Does the storage time of transfused red blood cells influence regional or global indexes of tissue oxygenation in anemic critically ill patients? Crit Care Med 2004; 32:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/13\">",
"      Mannucci PM, Federici AB, Sirchia G. Hemostasis testing during massive blood replacement. A study of 172 cases. Vox Sang 1982; 42:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/14\">",
"      Reed RL Jr, Ciavarella D, Heimbach DM, et al. Prophylactic platelet administration during massive transfusion. A prospective, randomized, double-blind clinical study. Ann Surg 1986; 203:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/15\">",
"      Simon GE, Bove JR. The potassium load from blood transfusion. Postgrad Med 1971; 49:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/16\">",
"      Baz EM, Kanazi GE, Mahfouz RA, Obeid MY. An unusual case of hyperkalaemia-induced cardiac arrest in a paediatric patient during transfusion of a 'fresh' 6-day-old blood unit. Transfus Med 2002; 12:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/17\">",
"      Smith HM, Farrow SJ, Ackerman JD, et al. Cardiac arrests associated with hyperkalemia during red blood cell transfusion: a case series. Anesth Analg 2008; 106:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/18\">",
"      Mount DB, Zandi-Nejad K. Disorders of potassium balance. In: Brenner BM, ed. Brenner and Rector's The Kidney. Philadelphia: WB Saunders 2004; :997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/19\">",
"      Perkins RM, Aboudara MC, Abbott KC, Holcomb JB. Resuscitative hyperkalemia in noncrush trauma: a prospective, observational study. Clin J Am Soc Nephrol 2007; 2:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/20\">",
"      Cid J, Ramiro L, Bertran S, et al. Efficacy in reducing potassium load in irradiated red cell bags with a potassium adsorption filter. Transfusion 2008; 48:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/21\">",
"      Strauss RG. Data-driven blood banking practices for neonatal RBC transfusions. Transfusion 2000; 40:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/22\">",
"      Casper JT, Varma RR, Lewis JD, et al. Exchange transfusion in Reye's syndrome with saline-washed red blood cells. Transfusion 1976; 16:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/23\">",
"      McMahon TJ, Moon RE, Luschinger BP, et al. Nitric oxide in the human respiratory cycle. Nat Med 2002; 8:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/24\">",
"      Doctor A, Platt R, Sheram ML, et al. Hemoglobin conformation couples erythrocyte S-nitrosothiol content to O2 gradients. Proc Natl Acad Sci U S A 2005; 102:5709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/25\">",
"      James PE, Lang D, Tufnell-Barret T, et al. Vasorelaxation by red blood cells and impairment in diabetes: reduced nitric oxide and oxygen delivery by glycated hemoglobin. Circ Res 2004; 94:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/26\">",
"      Bennett-Guerrero E, Veldman TH, Doctor A, et al. Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A 2007; 104:17063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/27\">",
"      Winslow RM, Intaglietta M. Red cell age and loss of function: advance or SNO-job? Transfusion 2008; 48:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/28\">",
"      Ho J, Sibbald WJ, Chin-Yee IH. Effects of storage on efficacy of red cell transfusion: when is it not safe? Crit Care Med 2003; 31:S687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/29\">",
"      Lelubre C, Piagnerelli M, Vincent JL. Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion 2009; 49:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/30\">",
"      Zubair AC. Clinical impact of blood storage lesions. Am J Hematol 2010; 85:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/31\">",
"      Baek JH, D'Agnillo F, Vallelian F, et al. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J Clin Invest 2012; 122:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/32\">",
"      Tinmouth A, Fergusson D, Yee IC, et al. Clinical consequences of red cell storage in the critically ill. Transfusion 2006; 46:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/33\">",
"      Zallen G, Offner PJ, Moore EE, et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg 1999; 178:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/34\">",
"      Purdy FR, Tweeddale MG, Merrick PM. Association of mortality with age of blood transfused in septic ICU patients. Can J Anaesth 1997; 44:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/35\">",
"      Vamvakas EC, Carven JH. Transfusion and postoperative pneumonia in coronary artery bypass graft surgery: effect of the length of storage of transfused red cells. Transfusion 1999; 39:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/36\">",
"      Basran S, Frumento RJ, Cohen A, et al. The association between duration of storage of transfused red blood cells and morbidity and mortality after reoperative cardiac surgery. Anesth Analg 2006; 103:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/37\">",
"      Mynster T, Nielsen HJ, Danish RANX05 Colorectal Cancer Study Group. Storage time of transfused blood and disease recurrence after colorectal cancer surgery. Dis Colon Rectum 2001; 44:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/38\">",
"      Offner PJ, Moore EE, Biffl WL, et al. Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg 2002; 137:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/39\">",
"      Leal-Noval SR, Jara-L&oacute;pez I, Garc&iacute;a-Garmendia JL, et al. Influence of erythrocyte concentrate storage time on postsurgical morbidity in cardiac surgery patients. Anesthesiology 2003; 98:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/40\">",
"      Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/41\">",
"      Leal-Noval SR, Mu&ntilde;oz-G&oacute;mez M, Arellano-Orden V, et al. Impact of age of transfused blood on cerebral oxygenation in male patients with severe traumatic brain injury. Crit Care Med 2008; 36:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/42\">",
"      Weinberg JA, McGwin G Jr, Marques MB, et al. Transfusions in the less severely injured: does age of transfused blood affect outcomes? J Trauma 2008; 65:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/43\">",
"      Eikelboom JW, Cook RJ, Liu Y, Heddle NM. Duration of red cell storage before transfusion and in-hospital mortality. Am Heart J 2010; 159:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/44\">",
"      Edgren G, Kamper-J&oslash;rgensen M, Eloranta S, et al. Duration of red blood cell storage and survival of transfused patients (CME). Transfusion 2010; 50:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/45\">",
"      Gauvin F, Spinella PC, Lacroix J, et al. Association between length of storage of transfused red blood cells and multiple organ dysfunction syndrome in pediatric intensive care patients. Transfusion 2010; 50:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/46\">",
"      Sanders J, Patel S, Cooper J, et al. Red blood cell storage is associated with length of stay and renal complications after cardiac surgery. Transfusion 2011; 51:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/47\">",
"      van de Watering L, Lorinser J, Versteegh M, et al. Effects of storage time of red blood cell transfusions on the prognosis of coronary artery bypass graft patients. Transfusion 2006; 46:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/48\">",
"      Vamvakas EC, Carven JH. Length of storage of transfused red cells and postoperative morbidity in patients undergoing coronary artery bypass graft surgery. Transfusion 2000; 40:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/49\">",
"      Weiskopf RB, Feiner J, Hopf H, et al. Fresh blood and aged stored blood are equally efficacious in immediately reversing anemia-induced brain oxygenation deficits in humans. Anesthesiology 2006; 104:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/50\">",
"      Vamvakas EC. Meta-analysis of clinical studies of the purported deleterious effects of \"old\" (versus \"fresh\") red blood cells: are we at equipoise? Transfusion 2010; 50:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/51\">",
"      Vamvakas EC. Purported deleterious effects of \"old\" versus \"fresh\" red blood cells: an updated meta-analysis. Transfusion 2011; 51:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/52\">",
"      Phelan HA, Eastman AL, Aldy K, et al. Prestorage leukoreduction abrogates the detrimental effect of aging on packed red cells transfused after trauma: a prospective cohort study. Am J Surg 2012; 203:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/53\">",
"      Kor DJ, Kashyap R, Weiskopf RB, et al. Fresh red blood cell transfusion and short-term pulmonary, immunologic, and coagulation status: a randomized clinical trial. Am J Respir Crit Care Med 2012; 185:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/54\">",
"      Kiraly LN, Underwood S, Differding JA, Schreiber MA. Transfusion of aged packed red blood cells results in decreased tissue oxygenation in critically injured trauma patients. J Trauma 2009; 67:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/55\">",
"      Donadee C, Raat NJ, Kanias T, et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation 2011; 124:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/56\">",
"      Hod EA, Brittenham GM, Billote GB, et al. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. Blood 2011; 118:6675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/57\">",
"      Adamson JW. New blood, old blood, or no blood? N Engl J Med 2008; 358:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/58\">",
"      Bennett-Guerrero E, Stafford-Smith M, Waweru PM, et al. A prospective, double-blind, randomized clinical feasibility trial of controlling the storage age of red blood cells for transfusion in cardiac surgical patients. Transfusion 2009; 49:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/59\">",
"      Steiner ME, Stowell C. Does red blood cell storage affect clinical outcome? When in doubt, do the experiment. Transfusion 2009; 49:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/60\">",
"      Rao SV, Califf RM. Is old blood bad blood? Am Heart J 2010; 159:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/61\">",
"      Mini-symposium on RBC storage. Transfusion 2011; 51:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/62\">",
"      van de Watering L, Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Pitfalls in the current published observational literature on the effects of red blood cell storage. Transfusion 2011; 51:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/63\">",
"      Lipson SM, Shepp DH, Match ME, et al. Cytomegalovirus infectivity in whole blood following leukocyte reduction by filtration. Am J Clin Pathol 2001; 116:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/64\">",
"      Rosenbaum L, Tomasulo P, Lipton KS, Ness P. The reintroduction of nonleukoreduced blood: would patients and clinicians agree? Transfusion 2011; 51:2739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/65\">",
"      G&oacute;es EG, Borges JC, Covas DT, et al. Quality control of blood irradiation: determination T cells radiosensitivity to cobalt-60 gamma rays. Transfusion 2006; 46:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/66\">",
"      Treleaven J, Gennery A, Marsh J, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol 2011; 152:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/67\">",
"      Hillyer CD, Tiegerman KO, Berkman EM. Evaluation of the red cell storage lesion after irradiation in filtered packed red cell units. Transfusion 1991; 31:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/68\">",
"      Davey RJ, McCoy NC, Yu M, et al. The effect of prestorage irradiation on posttransfusion red cell survival. Transfusion 1992; 32:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/69\">",
"      G&oacute;es EG, Ottoboni MA, Palma PV, et al. Quality control of blood irradiation with a teletherapy unit: damage to stored red blood cells after cobalt-60 gamma irradiation. Transfusion 2008; 48:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/70\">",
"      Relevy H, Koshkaryev A, Manny N, et al. Blood banking-induced alteration of red blood cell flow properties. Transfusion 2008; 48:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/71\">",
"      Zimmermann R, Wintzheimer S, Weisbach V, et al. Influence of prestorage leukoreduction and subsequent irradiation on in vitro red blood cell (RBC) storage variables of RBCs in additive solution saline-adenine-glucose-mannitol. Transfusion 2009; 49:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/72\">",
"      Lecak J, Scott K, Young C, et al. Evaluation of red blood cells stored at -80 degrees C in excess of 10 years. Transfusion 2004; 44:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/73\">",
"      Fabricant L, Kiraly L, Wiles C, et al. Cryopreserved deglycerolized blood is safe and achieves superior tissue oxygenation compared with refrigerated red blood cells: a prospective randomized pilot study. J Trauma Acute Care Surg 2013; 74:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/74\">",
"      Olsson ML, Clausen H. Modifying the red cell surface: towards an ABO-universal blood supply. Br J Haematol 2008; 140:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/75\">",
"      Bagnis C, Chiaroni J, Bailly P. Elimination of blood group antigens: hope and reality. Br J Haematol 2011; 152:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21081/abstract/76\">",
"      Giarratana MC, Rouard H, Dumont A, et al. Proof of principle for transfusion of in vitro-generated red blood cells. Blood 2011; 118:5071.",
"     </a>",
"    </li>",
"    <li>",
"     AABB Technical Manual, 17th, Roback JD, Grossman BJ, Harris T, et al.  (Eds), American Association of Blood Banks Press, Bethesda, MD 2011. p.237.",
"    </li>",
"    <li>",
"     AABB, American Red Cross, America&rsquo;s Blood Centers, and Armed Services Blood Program. Circular of Information for the use of human blood and blood components. file://www.aabb.org/resources/bct/Documents/coi0809r.pdf.",
"    </li>",
"    <li>",
"     Guidelines for the Administration of Blood Products. Australian and New Zealand Society of Blood Transfusion Ltd and Royal College of Nursing Australia, 2nd ed, Sydney Australia, December 2011. file://www.anzsbt.org.au/publications/documents/ANZSBT_Guidelines_Administration_Blood_Products_2ndEd_Dec_2011_Hyperlinks.pdf (Accessed on January 22, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7939 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-481C146FAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21081=[""].join("\n");
var outline_f20_37_21081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22828480\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COLLECTION AND STORAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preservative solutions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Storage bags",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHOICE OF COMPONENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHYSIOLOGIC CHANGES WITH STORAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Red cell viability and recovery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      2,3 BPG concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Potassium leakage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13954554\">",
"      - Hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13954561\">",
"      - Irradiated red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ammonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical relevance of storage time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SPECIALIZED RBC COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Leukoreduced red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Irradiated red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Washed red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Frozen deglycerolized red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Elimination of blood group antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21832187\">",
"      Ex vivo generation of red cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5049651\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22828480\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7939\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7939|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/37/10844\" title=\"table 1\">",
"      Irradiation blood indications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=related_link\">",
"      Administration and complications of red cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=related_link\">",
"      Compatibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27591?source=related_link\">",
"      Fluid and electrolyte therapy in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=related_link\">",
"      Indications for red blood cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38982?source=related_link\">",
"      Inhaled nitric oxide in adults with pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6361?source=related_link\">",
"      Peripheral venous access in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=related_link\">",
"      Preparation of blood components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=related_link\">",
"      Red blood cell transfusions in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=related_link\">",
"      Red cell transfusion in infants and children: Selection of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_37_21082="Regulation of iron balance";
var content_f20_37_21082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Regulation of iron balance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/37/21082/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/37/21082/contributors\">",
"     Clara Camaschella, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/37/21082/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/37/21082/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/37/21082/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/37/21082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/37/21082/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/37/21082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regulation of iron metabolism involves the interaction of a number of specific proteins as well as the interplay between iron absorption, recycling, and iron loss. This topic review will discuss these factors. Disorders of iron balance, both iron deficiency and iron overload, are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15257196\">",
"    <span class=\"h1\">",
"     ROLE OF SPECIFIC PROTEINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our current understanding of iron metabolism and the hallmarks of iron deficiency and excess is based upon the biology of a number of critical proteins including, but not limited to, the following [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transferrin (Tf)",
"     </li>",
"     <li>",
"      Transferrin receptor (TfR)",
"     </li>",
"     <li>",
"      Ferritin (Ft)",
"     </li>",
"     <li>",
"      Iron regulatory protein 1 and 2 (IRP1 and IRP2), the cellular iron sensing proteins",
"     </li>",
"     <li>",
"      Divalent metal transporter 1 (DMT1, Nramp2, DCT1, Solute carrier family 11, member 2 (SLC11A2)), the duodenal iron transporter",
"     </li>",
"     <li>",
"      Ferroportin (Ireg1, SLC11A3, Mtp1), the cellular iron exporter",
"     </li>",
"     <li>",
"      Hephaestin, which likely cooperates with ferroportin for exporting iron from enterocytes to transferrin",
"     </li>",
"     <li>",
"      Ceruloplasmin, a plasma metalloprotein required by ferroportin to export iron from macrophages, hepatocytes, and glial cells",
"     </li>",
"     <li>",
"      HFE, mutations of which are responsible for the common form of hereditary hemochromatosis",
"     </li>",
"     <li>",
"      TFR2, mutations of which are responsible for a rare form of hereditary hemochromatosis",
"     </li>",
"     <li>",
"      Hemojuvelin, a hepcidin regulator, mutations of which are responsible for the common form of juvenile hemochromatosis",
"     </li>",
"     <li>",
"      Hepcidin, the key negative regulator of intestinal iron absorption as well as macrophage iron release. Mutations of hepcidin cause a rare form of juvenile hemochromatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bone morphogenetic protein 6 (BMP6), a cytokine produced in iron overload, responsible for the main pathway of hepcidin activation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transferrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene for apotransferrin is on the long arm chromosome 3. It codes for a protein (mol wt 80 kDa) that tightly binds one or two ferric (Fe3+) molecules and is the major transporter for iron trafficking through the plasma. Most of the Tf, which has a half life of eight days, is made in the liver where its synthesis is considerably increased in states of iron deficiency by unknown mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tf can be measured in the plasma using an ELISA or turbidometric method to determine the mg of the transferrin",
"      <span class=\"nowrap\">",
"       protein/dL",
"      </span>",
"      of plasma.",
"     </li>",
"     <li>",
"      The total iron binding capacity of Tf (ie, TIBC) can be measured directly using iron binding methodology (ie, mg of iron binding",
"      <span class=\"nowrap\">",
"       capacity/dL",
"      </span>",
"      of plasma), or it can be calculated by multiplying the results of the chemical or immunologic method by a conversion factor calculated by the individual laboratory.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;TIBC (microg",
"    <span class=\"nowrap\">",
"     Fe/dL)",
"    </span>",
"    &nbsp;= &nbsp;Tf (mg",
"    <span class=\"nowrap\">",
"     protein/dL)",
"    </span>",
"    x (conversion factor)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (Conversion factor range: 1.40 to 1.49)",
"   </p>",
"   <p>",
"    Complete lack of transferrin is most likely incompatible with life. Hypotransferrinemia is a rare recessive disorder associated with low transferrin levels (&lt;10",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    severe iron deficiency anemia, and iron overloading of the liver and other parenchymal organs. Treatment is based on transferrin replacement via the use of plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Transferrin saturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating transferrin normally is about one-third saturated with iron (ie,",
"    <span class=\"nowrap\">",
"     Fe/TIBC",
"    </span>",
"    =",
"    <span class=\"nowrap\">",
"     1/3,",
"    </span>",
"    when both are expressed as micrograms of iron per 100 mL of plasma) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. See the formula directly above to change transferrin levels from mg of protein to mg of iron binding capacity if this has not already been provided by your laboratory.",
"   </p>",
"   <p>",
"    Conditions in which transferrin saturation is",
"    <strong>",
"     reduced",
"    </strong>",
"    include those in which the supply of iron to the plasma from the macrophage and other storage sites is reduced. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Iron deficiency anemia",
"     </li>",
"     <li>",
"      The anemia of chronic disease (anemia of chronic inflammation)",
"     </li>",
"     <li>",
"      Some patients with a ferroportin mutation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Ferroportin'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H16#H16\">",
"       \"Genetics of hereditary hemochromatosis\", section on 'Ferroportin mutations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conversely, transferrin saturation is",
"    <strong>",
"     increased",
"    </strong>",
"    in those conditions in which the supply of iron is excessive or is greater than the current demand. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Most cases of hereditary and acquired hemochromatosis",
"     </li>",
"     <li>",
"      Aplastic anemia, bone marrow suppression",
"     </li>",
"     <li>",
"      Sideroblastic anemias",
"     </li>",
"     <li>",
"      Ineffective erythropoiesis",
"     </li>",
"     <li>",
"      Liver disease with reduced transferrin synthesis",
"     </li>",
"     <li>",
"      Monoclonal immunoglobulin with antitransferrin activity (rare) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transferrin receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene for the TfR is also located on the long arm of chromosome 3. It codes for a homodimeric transmembrane protein (mol wt 94 kDa) that is found on most cells, but most densely on erythroid precursors and placental cells. There is a binding site for the transcription factor Stat5 in the first intron of the TfR gene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/12\">",
"     12",
"    </a>",
"    ]. Expression of constitutively active Stat5A in an erythroid cell line increased TrF1 levels, while lethally irradiated mice that received a transplant of",
"    <span class=\"nowrap\">",
"     Stat5a/b",
"    </span>",
"    <span class=\"nowrap\">",
"     (-/-)",
"    </span>",
"    liver cells developed microcytic, hypochromic anemia.",
"   </p>",
"   <p>",
"    Each TfR molecule can bind two diferric Tf molecules (four Fe3+ atoms), which it endocytoses after clustering on clathrin coated pits. The iron is off loaded in acidified vacuoles and the apotransferrin-TfR complex is recycled to the cell surface where apo-Tf is discharged and released back into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/13\">",
"     13",
"    </a>",
"    ]. As occurs in other iron genes, TfR mRNA has a 3' IRE and is post-transcriptionally regulated by IRPs (see below).",
"   </p>",
"   <p>",
"    Inactivation of TfR in mice is embryonically lethal due to severe anemia and abnormal central nervous system development. Haploinsufficiency of TfR causes microcytosis and a reduction of total body iron [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum (soluble) TfR (sTfR) is a product of membrane TfR, which is released into the circulation by membrane proteases when TfR is not associated with its ligand, diferric transferrin, as occurs in iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/15\">",
"     15",
"    </a>",
"    ]. Levels of sTfR measured in sera correlate directly with erythropoietic expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H31#H31\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Serum transferrin receptor'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H14#H14\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Soluble transferrin receptor assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ferritin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ferritin is the cellular storage protein for iron. It is a huge (mol wt 440 kDa), 24 subunit protein consisting of light (L ferritin, 20 kd, gene on chromosome 19) and heavy chains (H ferritin, 21 kd, gene on chromosome 11) which can store up to 4500 atoms of iron within its spherical cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/17\">",
"     17",
"    </a>",
"    ]. H Ferritin possesses ferroxidase activity necessary for iron uptake by the ferritin molecule. An RNA binding protein (poly (rC)-binding protein 1, PCBP1) appears to be required as a cytosolic chaperone to deliver iron to ferritin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ferritin synthesis is subject to at least two levels of control, including DNA transcription via its promoter and mRNA translation via interactions with iron regulatory proteins (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Iron regulatory proteins and iron-responsive element binding protein'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ferritin is an acute phase reactant, and, along with transferrin and the transferrin receptor, is a member of the protein family that orchestrates cellular defense against oxidative stress and inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mice lacking H ferritin die early in gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/21\">",
"     21",
"    </a>",
"    ]. Mice heterozygous for H ferritin have slightly elevated tissue L ferritin and 7- to 10-fold more serum L ferritin than normal mice, although they do not have tissue iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/22\">",
"     22",
"    </a>",
"    ]. These observations suggest that reduced H ferritin expression in man might be responsible for cases in which high serum ferritin is present in the absence of iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/22\">",
"     22",
"    </a>",
"    ]. Conditional inactivation of H ferritin in duodenal cells in mice causes iron overload, indicating that ferritin in the gut is important in the control of iron absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Much of the iron stored in ferritin is accessible for metabolic needs. Ferritin within erythroid precursors may be of special importance in the donation of iron for heme synthesis, especially at the beginning of hemoglobin accumulation, at a time when the transferrin-transferrin receptor pathway is still insufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/24\">",
"     24",
"    </a>",
"    ]. When ferritin accumulates, it aggregates and is proteolyzed by lysosomal enzymes; it is then converted to an iron-rich, poorly characterized hemosiderin which releases its iron slowly and is detected in cells by the Prussian blue reaction.",
"   </p>",
"   <p>",
"    Ferritin measured clinically in plasma is usually apoferritin, a non-iron containing molecule. The plasma level generally reflects overall iron storage, with 1 ng of ferritin per mL indicating approximately 10 mg of total iron stores. Thus,",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A normal adult male with a plasma ferritin level of 50 to 100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      has iron stores of approximately 500 to 1000 mg [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A serum ferritin less than 10 to 15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      is 99 percent specific for making a diagnosis of iron deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H26#H26\">",
"       \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Serum or plasma ferritin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An elevated serum ferritin in the absence of infection or inflammation suggests the presence of an iron overload state. This subject is discussed in depth separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H13#H13\">",
"       \"Genetics of hereditary hemochromatosis\", section on 'Other gene defects leading to iron overload or high ferritin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ferritin levels may be extremely high in patients with hemophagocytic lymphohistiocytosis or certain rheumatologic disorders. In such cases, the ferritin tends to be less glycosylated than normal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H24#H24\">",
"       \"Hemophagocytic lymphohistiocytosis\", section on 'Ferritin levels'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate ferritin (m-ferritin) is present within mitochondria and is the product of an intronless nuclear gene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/26\">",
"     26",
"    </a>",
"    ]. Its expression is increased in tissues with high numbers of mitochondria, rather than in tissues involved in iron storage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/27\">",
"     27",
"    </a>",
"    ]. M-ferritin likely protects mitochondria from oxidative damage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Iron regulatory proteins and iron-responsive element binding protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The expression of proteins involved in cellular iron uptake and storage is regulated by the iron status of the cell. Iron-regulatory proteins 1 and 2 (IRP1 and IRP2) are cytosolic RNA-binding proteins that bind to iron-responsive elements (IRE), consisting of a loop configuration of nucleotides, that are located in the 5'- or 3'-untranslated regions (UTR) of specific mRNAs encoding for iron genes (eg, ferritin, TfR, DMT1, ferroportin and the erythroid specific form of delta-aminolevulinic acid synthase (eALAS)) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Binding of IRPs to their target sequences occurs when the cell is iron deficient and has different effects according to whether the IRE position is at the 5' or the 3' UTR, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When IRPs bind to the 5' IRE of ferritin, ferroportin, or eALAS, the rates of biosynthesis are decreased.",
"     </li>",
"     <li>",
"      When IRPs bind to the 3' end of transcripts such as TfR or DMT1, the mRNA half-life is prolonged and rates of biosynthesis are increased (",
"      <a class=\"graphic graphic_figure graphicRef56268 \" href=\"UTD.htm?4/36/4672\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IRP1 and IRP2 sense the state of the iron balance in the cell in different ways. When cellular iron levels increase, assembly with iron sulfur clusters changes IRP1 aconitase and its binding ability is lost. Under the same conditions of cellular iron increase, IRP2 interacts with the iron stabilized FBXL5 protein, which recruits an E3 ligase [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] addressing IRP2 to ubiquitination and proteasome degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is that the iron overloaded state is characterized by increased production of ferritin (to permit adequate storage) and decreased production of TfR (to minimize iron uptake). These changes are reversed in iron deficiency, which is characterized by reduced ferritin and elevated TfR synthesis (",
"    <a class=\"graphic graphic_figure graphicRef56268 \" href=\"UTD.htm?4/36/4672\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Targeted deletion of the gene encoding IRP1 in the mouse leads to no evident hematologic change, while targeted deletion of the gene encoding IRP2 causes misregulation of iron metabolism, refractory microcytic anemia, and a neurodegenerative disease due to abnormal neuronal accumulation of iron [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. These observations establish a major role for IRP2 in the regulation of iron uptake in erythroid cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     HFE protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;HFE, a product of the HFE gene on the short arm of chromosome 6, is expressed ubiquitously at low levels, but at high levels in hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/35\">",
"     35",
"    </a>",
"    ]. Mutations in the HFE gene are responsible for the vast majority of patients with hereditary hemochromatosis; iron overload is also noted in HFE knockout mice [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/36\">",
"     36",
"    </a>",
"    ]. Conditional deletion of HFE in the liver produces the phenotype of hemochromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/37\">",
"     37",
"    </a>",
"    ], whereas conditional deletion in duodenal cells or macrophages does not alter iron metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The HFE protein is associated in a complex with TfR. The role of the HFE protein in this complex is unclear, but diferric transferrin competes with this binding. In addition, the function of the HFE-TfR complex is linked to the response of hepcidin to iron availability in some, as yet incompletely understood, manner, since patients with hemochromatosis due to an HFE mutation have low hepcidin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/39-41\">",
"     39-41",
"    </a>",
"    ] and do not respond to oral iron challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H10#H10\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Role in iron absorption'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Hepcidin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    HFE is also able to bind TfR2, a gene mutated in type 3 hereditary hemochromatosis, which is considered to be a sensor of the level of transferrin saturation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Loss of both HFE and TFR2 in double knockout mice results in marked dysregulation of hepcidin and more severe iron overload than loss of the single molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1230249\">",
"    <span class=\"h2\">",
"     Transferrin receptor 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transferrin receptor 2 (TfR2) is a member of the TfR family and is homologous to TfR1, but has no IRE elements and has a low affinity for transferrin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/45\">",
"     45",
"    </a>",
"    ]. It displays a restricted expression pattern, being present at high levels in hepatocytes. TfR2 may bind diferric transferrin and HFE [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/42,43\">",
"     42,43",
"    </a>",
"    ] and is considered a sensor of Tf saturation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. TFR2 is expressed in immature erythroid cells where it interacts with the erythropoietin receptor, stabilizing it on the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations of TFR2 cause a form of hereditary hemochromatosis and mice with either germline or liver conditional inactivation of TFR2 develop iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/44,50,51\">",
"     44,50,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H15#H15\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Transferrin receptor 2 mutation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1229645\">",
"    <span class=\"h2\">",
"     Hemojuvelin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemojuvelin is a GPI anchored protein that regulates hepcidin production. It is homologous to RGM (Repulsive Guidance Molecule) expressed in the central nervous system. Mutations of HJV produce the common form of juvenile hemochromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H14#H14\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Juvenile hemochromatosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HJV is present in a membrane-associated form and also as a soluble form with opposite effects on hepcidin activation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Membrane HJV is a coreceptor for Bone Morphogenetic Proteins (BMPs) and is involved in hepcidin activation. Soluble HJV is produced by furin cleavage in hypoxia and iron deficiency and serves to downregulate hepcidin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An immunoassay is now available for hemojuvelin, which should shed further light on its function as well as alterations in disease states [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Duodenal iron transporter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two approaches were used to identify a duodenal iron transporter which is believed to be the major route for the uptake of iron from the intestinal lumen. Positional cloning identified the gene responsible for a form of microcytic anemia in mice, (mk), which is associated with a marked impairment in intestinal ion transport [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/58\">",
"     58",
"    </a>",
"    ]. The mutation, a glycine to arginine missense mutation, was found in the Nramp2 gene of these animals. Nramp2 had been an orphan protein with no known function, cloned based on its homology to Nramp1, a molecule involved in macrophage host defense, the Natural-Resistance-Associated Macrophage Protein.",
"   </p>",
"   <p>",
"    Parallel functional studies in Xenopus oocytes found a single cDNA that stimulated iron transport. This divalent metal transporter protein (DMT1), was identical to Nramp2 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/59\">",
"     59",
"    </a>",
"    ]. The transporter also transports other heavy metals such as lead, zinc, and copper coupled with protons. DMT1 is widely expressed, particularly in the proximal duodenum. Expression of the isoform containing an iron responsive element (Nramp 2 isoform I) is specifically upregulated in dietary iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/58,60\">",
"     58,60",
"    </a>",
"    ] and hypoxia through the action of HIF-2alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/61\">",
"     61",
"    </a>",
"    ], with greatest expression at the brush border of the apical pole of the enterocytes in the apical two-thirds of the villi, the major site of iron absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DMT1 (SLC11A2 gene) mutations in humans cause life-long microcytic anemia, increased Tf saturation, and liver iron accumulation, but with low or only moderately high serum ferritin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/62-66\">",
"     62-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Duodenal cytochrome b",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duodenal cytochrome b (Dcytb) is a membrane reductase that facilitates iron absorption as ferrous iron from the lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Iron exporters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once iron is absorbed by the enterocyte, it must be exported from the basolateral portion of the cell into the circulation. Similarly, iron in the macrophage from recycled red cells must also be exported into the circulation. A single cellular iron exporter, ferroportin, has been described, and is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ferroportin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ferroportin-1 (Ireg1, SLC11A3, Mtp1), has been found by positional cloning in the mutant zebrafish with hypochromic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/68\">",
"     68",
"    </a>",
"    ]. When expressed in Xenopus oocytes, Zebrafish ferroportin-1 acts as an iron exporter. Human ferroportin-1 has been found in the basal portion of the placental syncytiotrophoblasts, the basolateral surface of duodenal enterocytes, macrophages, and hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. The ferroportin gene maps to 2q32.",
"   </p>",
"   <p>",
"    Ferroportin functions as a major exporter of iron, transporting iron from mother to fetus, transferring absorbed iron from enterocytes into the circulation, and allowing macrophages to recycle iron from damaged red cells back into the circulation. In animal and human in vitro models, ferroportin-1 is posttranscriptionally regulated by the amount of available iron, due to the presence of a 5&rsquo; UTR iron responsive element [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. An isoform of ferroportin without 5&rsquo; IRE (ferroportin B) has been identified in duodenal mucosa. It would appear to function to evade iron-mediated post-transcriptional regulation in conditions of iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/74\">",
"     74",
"    </a>",
"    ]. The same isoform is expressed in erythroblasts, and may function to &ldquo;fine-tune&rdquo; systemic iron utilization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the most important control of ferroportin is posttranscriptional, since ferroportin is downregulated through its interaction with hepcidin (",
"    <a class=\"graphic graphic_figure graphicRef66578 \" href=\"UTD.htm?38/11/39088\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/70,73,77,78\">",
"     70,73,77,78",
"    </a>",
"    ]. When hepcidin levels increase, hepcidin binds to ferroportin and induces its internalization and lysosomal degradation. This reduces the amount of iron that is released into the circulation from duodenal cells as well as macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ferroportin mutations have been found in a number of families with an autosomal dominant form of hereditary hemochromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H16#H16\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Ferroportin mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hephaestin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hephaestin is the product of an X-linked gene mutated in mice with sex-linked anemia, a disorder in which enterocytes are iron-loaded but efflux of iron through the basolateral membrane and into the plasma is inhibited [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/82\">",
"     82",
"    </a>",
"    ]. Hephaestin has significant homology to the copper-containing serum protein ceruloplasmin, a ferroxidase required for efficient recycling of iron in the liver, reticuloendothelial system, and blood and likely cooperates with ferroportin for exporting iron to transferrin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Heme exporter",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mammalian heme export protein has been described (FLVCR, feline leukemia virus, subgroup C, receptor), which has been postulated to protect developing erythroid cells from the toxicity of unbound cytoplasmic heme. Interference with this protein results in a loss of erythroid progenitors and severe anemia in experimental animals, while its inhibition in human erythroleukemia cells decreases heme export, impairs their erythroid maturation, and leads to apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hepcidin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepcidin (liver-expressed antimicrobial peptide, LEAP-1) is an acute phase reactant produced in the liver, with intrinsic antimicrobial activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/85-90\">",
"     85-90",
"    </a>",
"    ]. There are two isoforms; hepcidin-25 has a central role in iron homeostasis, while the function of hepcidin-20, which lacks the five amino acid sequence crucial for iron regulation, is unknown. The importance of hepcidin is shown in the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepcidin knockout mice develop iron overload [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/87,91\">",
"       87,91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Constitutive overexpression of hepcidin leads to severe iron deficiency anemia at birth [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/92\">",
"       92",
"      </a>",
"      ], and slows dietary iron absorption and cycling through macrophages, resulting in iron-restricted erythropoiesis and a failure to respond to adequate erythropoietin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overexpression of hepcidin inhibits the iron accumulation normally observed in HFE-deficient mice [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/94,95\">",
"       94,95",
"      </a>",
"      ] and in mouse models of beta thalassemia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In humans, mutation in hepcidin cause juvenile forms of hemochromatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H14#H14\">",
"       \"Genetics of hereditary hemochromatosis\", section on 'Juvenile hemochromatosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hepcidin is upregulated in response to increased body iron levels, inflammation, infection, endotoxin, and p53, and is downregulated following hypoxia, anemia, iron deficiency, severe ineffective erythropoiesis, as well as by increased levels of erythropoietin or growth differentiation factor 15 (GDF15) (",
"    <a class=\"graphic graphic_figure graphicRef64022 \" href=\"UTD.htm?1/56/1927\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/97-102\">",
"     97-102",
"    </a>",
"    ]. Hepcidin has also been shown to be regulated by a transferrin-dependent pathway in the zebrafish embryo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wide confidence limits for hepcidin levels in normal subjects were noted in three reports [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/104-106\">",
"     104-106",
"    </a>",
"    ]. When more rigorous criteria for controls were required (eg, normal iron studies, and no evidence for inflammation, hepatic, or renal disease), variability was considerably less [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/107\">",
"     107",
"    </a>",
"    ]. Initiatives are ongoing for standardization of hepcidin assays [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/108\">",
"     108",
"    </a>",
"    ]. Two large studies have measured serum hepcidin in the general population. In the first study, hepcidin levels were analyzed using a competitive enzyme-linked immunoabsorbent assay in 2998 well-characterized participants from the Nijmegen Biomedical Study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/109\">",
"     109",
"    </a>",
"    ]. In the second report, serum hepcidin levels were measured by mass spectrometry in 1545 subjects from an Italian cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both studies observed stable values in males across ages but strong variation in females, with low values in younger and higher levels in older females [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was a trend of increasing hepcidin concentrations during the day, although there was no evidence for a primary or secondary circadian variation in hepcidin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Levels were strongly associated with serum ferritin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/109\">",
"       109",
"      </a>",
"      ], and were less strongly associated with C-reactive protein and total iron binding capacity (TIBC) in men and for TIBC, alanine aminotransferase, and glomerular filtration rate in women [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Because of the lack of a standardized assay, we have concluded that hepcidin testing is not ready for regular clinical use at this time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the genetic basis of this variation is poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/111\">",
"     111",
"    </a>",
"    ], serum hepcidin levels have correlated directly with serum ferritin in healthy subjects, were highest in inflammation, and lowest in iron deficiency anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/104,107\">",
"     104,107",
"    </a>",
"    ]. Alpha-2 macroglobulin may be the hepcidin transporter in blood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injection of hepcidin inhibited intestinal iron absorption in mice independent of their iron status, and did not require the HFE gene product [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/113\">",
"       113",
"      </a>",
"      ]. In other experiments, injection of a synthetic hepcidin in mice was associated with a rapid and prolonged reduction in serum iron, along with accumulation of hepcidin in ferroportin-rich organs (eg, liver, spleen, proximal duodenum) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iron-free diet, anemia, and hypoxia are associated with decreased hepcidin production. Hypoxia causes stabilization of Hif-1-alpha that interacts with an hypoxia-related element (HRE) of the hepcidin promoter to inhibit hepcidin transcription [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/114\">",
"       114",
"      </a>",
"      ]. Hypoxia also induces the release of soluble hemojuvelin [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/55\">",
"       55",
"      </a>",
"      ], an inhibitor of hepcidin upregulation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hepcidin response to increased plasma or tissue iron is mediated by bone morphogenetic proteins (BMP), requires hemojuvelin as a BMP coreceptor, and is SMAD-dependent (",
"    <a class=\"graphic graphic_figure graphicRef64022 \" href=\"UTD.htm?1/56/1927\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/54,115-117\">",
"     54,115-117",
"    </a>",
"    ]. BMP6-null mice have a phenotype resembling hereditary hemochromatosis, with reduced hepcidin expression and tissue iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/6,118\">",
"     6,118",
"    </a>",
"    ], indicating the essential role of BMP6 in iron regulation in mammals. In a mouse model, iron overload induced BMP6 mRA and protein expression in the liver but not in the duodenum, strongly supporting the importance of liver BMP6 for regulation of iron metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased hepcidin production is seen in the acute inflammation mediated by lipopolysaccharide, IL-6 and IL-1 (",
"    <a class=\"graphic graphic_figure graphicRef64022 \" href=\"UTD.htm?1/56/1927\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/120,121\">",
"     120,121",
"    </a>",
"    ] as well as following the absorption of amounts of iron sufficient to acutely increase transferrin saturation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above observations suggest that hepcidin, and perhaps other regulatory molecules produced in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/122,123\">",
"     122,123",
"    </a>",
"    ], plays a major role as a negative regulator of intestinal iron absorption and iron release from macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/88,124\">",
"     88,124",
"    </a>",
"    ], by interacting with, and inactivating, the iron export protein ferroportin (",
"    <a class=\"graphic graphic_figure graphicRef66578 \" href=\"UTD.htm?38/11/39088\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepcidin may also serve as an important mediator in the pathogenesis of the anemia of chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/85,120,121,123,125,126\">",
"     85,120,121,123,125,126",
"    </a>",
"    ] and its deficiency or inappropriate production explains the pathogenesis of hereditary hemochromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/39,40,94,123,127,128\">",
"     39,40,94,123,127,128",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H2#H2\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H8#H8\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Potential role of hepcidin or hemojuvelin mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has also been suggested that hepcidin, interacting with ferroportin, plays the function of modulating acute inflammatory response in vivo in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1230379\">",
"    <span class=\"h3\">",
"     Iron sensing and signaling pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The iron sensing and signaling pathway involving hepcidin is complex and not fully elucidated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/130\">",
"     130",
"    </a>",
"    ]. The proposed model is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef64022 \" href=\"UTD.htm?1/56/1927\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BMP6 in iron overload activates its own receptors (BMPR) in the presence of the coreceptor HJV. In agreement, BMP6 inactivation in mice causes severe iron overload with low hepcidin [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/6,118\">",
"       6,118",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Signal transduction of BMPs occurs through SMAD proteins; conditional inactivation of Smad4 in mouse liver causes liver iron accumulation and the inability to upregulate hepcidin, findings that are similar to those seen in hereditary hemochromatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Whether and how the HFE-TFR2 complex that is formed in the presence of increased diferric transferrin cooperates with the BMP-HJV-SMAD pathway for hepcidin activation remains to be defined. In HFE",
"      <span class=\"nowrap\">",
"       -/-",
"      </span>",
"      mice the BMP pathway is indeed less active and treatment with BMP6 appears to ameliorate iron overload [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/132\">",
"       132",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inflammatory cytokines, especially IL6 (and IL1beta) activate hepcidin transcription through interaction with IL6 receptor and signal transduction through STAT3 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/41,54,122,133\">",
"       41,54,122,133",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Whether there is a crosstalk between the two pathways of hepcidin activation is a matter of investigation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     The TMPRSS6 gene and matriptase-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most powerful inhibitor of hepcidin expression is matriptase-2, which is encoded by the transmembrane protease, serine 6 gene (TMPRSS6). Matriptase-2 exerts its hepcidin regulatory effects by cleaving hemojuvelin, a protein that normally signals to promote hepcidin expression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/134,135\">",
"     134,135",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1229645\">",
"     'Hemojuvelin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In agreement with hemojuvelin being the substrate of TMPRSS6, mice that are double knockout for both TMPRSS6 and HJV have the same phenotype as that of HJV",
"      <span class=\"nowrap\">",
"       -/-",
"      </span>",
"      mice [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Single nucleotide polymorphisms in the TMPRSS6 gene have been described in several ethnic populations, and appear to affect serum iron concentrations, hemoglobin levels, erythrocyte traits (eg, MCV, MCH), and, indirectly, erythropoiesis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/137-141\">",
"       137-141",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Iron-refractory iron deficiency anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations and polymorphisms of TMPRSS6 have been associated with a rare autosomal recessive disorder characterized by iron deficiency anemia unresponsive to treatment with oral iron, but partially responsive to parenteral iron therapy, a condition termed iron-refractory iron deficiency anemia (IRIDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/142\">",
"     142",
"    </a>",
"    ]. IRIDA is associated with inappropriately high levels of hepcidin, resulting in iron deficiency secondary to reduced gastrointestinal iron absorption and increased macrophage iron sequestration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/135,143-147\">",
"     135,143-147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TMPRSS6-haploinsufficient mice are similarly prone to iron deficiency when iron demands are high, or when dietary iron is restricted, as during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/136,148\">",
"     136,148",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     REGULATION OF IRON BALANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal iron content of the body is approximately 3 to 4 g. It exists in the following forms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin in circulating red cells and developing erythroblasts &mdash; about 2.5 g",
"     </li>",
"     <li>",
"      Iron-containing proteins (eg, myoglobin, cytochromes, catalase) &mdash; 400 mg",
"     </li>",
"     <li>",
"      Plasma transferrin-bound iron &mdash; 3 to 7 mg",
"     </li>",
"     <li>",
"      The remainder is storage iron in the form of ferritin or hemosiderin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adult men have about 1 g of storage iron (mostly in liver, spleen, and bone marrow). Adult women have less storage iron depending upon the extent of menses, pregnancies, deliveries, lactation, and iron intake. Only a small amount of iron enters and leaves the body on a daily basis. Most iron is recycled from the breakdown of old red blood cells by macrophages of the reticuloendothelial system. Essentially all circulating iron is bound to transferrin. This chelation renders the iron soluble and prevents iron-mediated free radical toxicity. The mechanism by which transferrin acquires iron from intestinal absorptive cells and reticuloendothelial cells is unknown. Iron homeostasis is regulated strictly at the level of intestinal absorption and release of iron from macrophages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intestinal iron absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal mucosa plays a major role in regulating iron absorption, which varies according to the form of iron in the diet [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/1\">",
"     1",
"    </a>",
"    ]. A Western daily diet contains about 15 mg of iron. Some of this is heme iron, of which about 30 percent is promptly absorbed, likely via its own transport system. A candidate heme iron transporter, named heme carrier protein 1, has been found in the apical brush border membrane of duodenal enterocytes in the mouse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/149\">",
"     149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The remaining iron, accounting for almost all of the iron in the diet in non-Western countries, is poorly absorbed, with less than 10 percent being taken into the mucosal cells (",
"    <a class=\"graphic graphic_figure graphicRef71736 \" href=\"UTD.htm?36/1/36895\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Heme dietary sources (fish, poultry, and meat) have a higher bioavailability than do non-heme (vegetable) sources (30 versus 10 percent). In addition, intraluminal factors can affect absorption (",
"    <a class=\"graphic graphic_table graphicRef64874 \" href=\"UTD.htm?26/5/26715\">",
"     table 1",
"    </a>",
"    ). Ascorbic acid enhances the absorption of non-animal sources of iron such as cereal, breads, fruits, and vegetables, whereas tannates (teas), bran foods rich in phosphates, and phytates inhibit iron absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/150-152\">",
"     150-152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Molecular mechanisms of intestinal heme absorption are unclear. The proposed heme carrier protein, which is highly expressed in the gut and stimulated by hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/149\">",
"     149",
"    </a>",
"    ], functions as a folate transporter [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/153\">",
"     153",
"    </a>",
"    ]. A heme exporter, Feline Leukemia Virus Receptor 5 (FLVR5) is expressed in enterocytes, macrophages and erythroblasts with the likely function of exporting heme excess [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Heme exporter'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Iron in food is prominently ferric (Fe3+), which is poorly soluble above a pH of 3 and is therefore poorly absorbed. In comparison, ferrous iron (Fe2+) is more soluble, even at the pH of seven to eight seen in the duodenum. As a result, it is more easily absorbed.",
"   </p>",
"   <p>",
"    Ferrous iron is taken up at the mucosal side by the intestinal transporter, DMT1 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/154\">",
"     154",
"    </a>",
"    ]. Transcription of both DMT1 and DcytB is stimulated by HIF2alpha in the hypoxic environment of intestinal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/61,155\">",
"     61,155",
"    </a>",
"    ]. In this process duodenal cytochrome b provides reduction of ferric to ferrous iron. The iron is thought to enter the cell where it binds to cytosolic low molecular weight iron carriers and is transported to the basolateral portion of the cell. To enter the circulation, iron must be transported across the basolateral membrane by the duodenal iron exporter, ferroportin. Upon its release, the ferrous iron is oxidized to the ferric form, and loaded onto transferrin. This oxidation process involves hephaestin, a homologue of ceruloplasmin, a known ferroxidase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal cells, in addition to the cellular mechanisms noted above, respond to specific physiologic signals (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Hepcidin'",
"    </a>",
"    above) (",
"    <a class=\"graphic graphic_figure graphicRef54929 \" href=\"UTD.htm?21/50/22318\">",
"     figure 5",
"    </a>",
"    ). The rate of iron absorption is appropriately enhanced when iron stores are reduced or absent. The degree of erythropoiesis also has an effect, as iron absorption is increased when there is increased erythropoiesis.",
"   </p>",
"   <p>",
"    In these conditions hepcidin must be downregulated, but the molecular mechanisms are still unclear. Candidate proteins for this function are cytokines produced by the erythroblasts, as growth differentiation factor 15 (GDF15), which is especially increased in serum of patients with homozygous beta-thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/156\">",
"     156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iron absorption is especially increased in disorders that cause ineffective erythropoiesis, such as beta thalassemia, sideroblastic anemia, or variants of the myelodysplastic syndrome. On the other hand, intestinal cells can hold onto iron in the iron-replete state; this iron is lost when the mucosal cells are sloughed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/2\">",
"     2",
"    </a>",
"    ]. All of these regulatory processes are mainly mediated by hepcidin through its interaction with ferroportin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/157,158\">",
"     157,158",
"    </a>",
"    ]. This function of hepcidin appears to be especially important when there are competing needs for iron, such as when anemia, iron deficiency, and infection coexist, as shown in African children in the malaria setting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/159\">",
"     159",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Iron loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no normal mechanism of regulated iron loss. Iron is lost in sweat, shed skin cells, and perhaps some gastrointestinal loss at a rate of approximately 1",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    A normal adult Western male has 1 to 2 mg of heme iron and 10 to 15 mg of other iron in his diet. If 30 percent of the heme iron and 10 percent of the other iron is absorbed, then the total rate of iron absorption is 1 to 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, a man can easily stay in iron balance and even build up iron stores. On the other hand, a woman with an additional menstrual iron loss of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    generally has lower iron stores than men, and is always delicately poised to become iron deficient (",
"    <a class=\"graphic graphic_table graphicRef76998 \" href=\"UTD.htm?15/22/15723\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is abundant expression of DMT1 in the proximal tubule and collecting ducts of the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/58\">",
"     58",
"    </a>",
"    ]. This raises the possibility that there is an iron excretory pathway that is overcome by constitutive reabsorption. If this hypothesis is correct, pharmacologic blockade of this pathway could represent an important therapeutic maneuver for syndromes of iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/160\">",
"     160",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Iron release from macrophages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 to 25 mg of iron are released daily from the breakdown of senescent red cells in the macrophages. Hemoglobin heme released from phagocytosed red cells is catabolized by microsomal heme oxygenase to biliverdin and carbon monoxide and the resulting free iron is released to the circulation through ferroportin or stored in ferritin according to the body needs and to the local concentration of hepcidin. Thus, hepcidin coordinates both duodenal iron absorption as well as macrophage iron release. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Hepcidin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Upon its release from ferroportin, ferrous iron is oxidized to the ferric form, and loaded onto transferrin. The oxidation process involves ceruloplasmin, a known copper dependent multioxidase. This could explain the iron overload that is seen in aceruloplasminemia, an autosomal recessive disorder of iron metabolism characterized by anemia, diabetes, retinal degeneration, and neurologic symptoms. Affected patients evidence inherited mutations in the ceruloplasmin gene, along with marked parenchymal iron accumulation in conjunction with an absence of circulating serum ceruloplasmin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/37/21082/abstract/161,162\">",
"     161,162",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H17#H17\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Aceruloplasminemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3572599\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regulation of iron metabolism involves the interaction of a number of specific proteins as well as the interplay between iron absorption from the gastrointestinal tract, recycling of iron from red cells at the end of their life span, release of iron stores from the monocyte-macrophage system, and iron loss from the body (",
"    <a class=\"graphic graphic_figure graphicRef71736 \" href=\"UTD.htm?36/1/36895\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Intestinal iron absorption",
"      </strong>",
"      &mdash; This function is tightly controlled, since there is no physiologic means of excreting iron from the body once it is absorbed (",
"      <a class=\"graphic graphic_figure graphicRef54929 \" href=\"UTD.htm?21/50/22318\">",
"       figure 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Intestinal iron absorption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Iron cycling",
"      </strong>",
"      &mdash; Ferroportin functions as a major exporter of iron, transporting iron from mother to fetus, transferring absorbed iron from enterocytes into the circulation, and allowing macrophages to recycle iron from damaged red cells back into the circulation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Iron exporters'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Iron release from macrophages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Hepcidin",
"      </strong>",
"      &mdash; The most important control of iron cycling through ferroportin is posttranscriptional, since ferroportin is downregulated through its interaction with hepcidin (",
"      <a class=\"graphic graphic_figure graphicRef66578 \" href=\"UTD.htm?38/11/39088\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hepcidin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Iron loss",
"      </strong>",
"      &mdash; Iron is lost in sweat, shed skin cells, and perhaps some gastrointestinal loss at a rate of approximately 1",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      A woman with an additional menstrual iron loss of 1 to 2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      generally has lower iron stores than men, and is always delicately poised to become iron deficient (",
"      <a class=\"graphic graphic_table graphicRef69390 \" href=\"UTD.htm?14/2/14379\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Iron loss'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H37#H37\">",
"       \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Search for source of blood and iron loss'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Brittenham GM. Disorders of iron metabolism: Iron deficiency and overload. In: Hematology Basic Principles and Practice, 4th ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2005. p.481.",
"    </li>",
"    <li>",
"     Beutler E. Disorders of iron metabolism. In: Williams Hematology, 7th ed, Lichtman MA, Beutler E, Kipps TJ, et al. (Eds), McGraw-Hill, New York 2006. p.511.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/3\">",
"      Andrews NC. Forging a field: the golden age of iron biology. Blood 2008; 112:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/4\">",
"      Camaschella C, Poggiali E. Inherited disorders of iron metabolism. Curr Opin Pediatr 2011; 23:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/5\">",
"      Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/6\">",
"      Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009; 41:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/7\">",
"      Goldwurm S, Casati C, Venturi N, et al. Biochemical and genetic defects underlying human congenital hypotransferrinemia. Hematol J 2000; 1:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/8\">",
"      Beutler E, Gelbart T, Lee P, et al. Molecular characterization of a case of atransferrinemia. Blood 2000; 96:4071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/9\">",
"      Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med 1982; 306:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/10\">",
"      Cook JD. Clinical evaluation of iron deficiency. Semin Hematol 1982; 19:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/11\">",
"      Alyanakian MA, Taes Y, Bensa&iuml;d M, et al. Monoclonal immunoglobulin with antitransferrin activity: A rare cause of hypersideremia with increased transferrin saturation. Blood 2007; 109:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/12\">",
"      Zhu BM, McLaughlin SK, Na R, et al. Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression. Blood 2008; 112:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/13\">",
"      Worwood M. An overview of iron metabolism at a molecular level. J Intern Med 1989; 226:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/14\">",
"      Levy JE, Jin O, Fujiwara Y, et al. Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat Genet 1999; 21:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/15\">",
"      Kaup M, Dassler K, Weise C, Fuchs H. Shedding of the transferrin receptor is mediated constitutively by an integral membrane metalloprotease sensitive to tumor necrosis factor alpha protease inhibitor-2. J Biol Chem 2002; 277:38494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/16\">",
"      Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/17\">",
"      Arosio P, Levi S. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim Biophys Acta 2010; 1800:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/18\">",
"      Shi H, Bencze KZ, Stemmler TL, Philpott CC. A cytosolic iron chaperone that delivers iron to ferritin. Science 2008; 320:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/19\">",
"      Hintze KJ, Theil EC. DNA and mRNA elements with complementary responses to hemin, antioxidant inducers, and iron control ferritin-L expression. Proc Natl Acad Sci U S A 2005; 102:15048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/20\">",
"      Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99:3505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/21\">",
"      Ferreira C, Bucchini D, Martin ME, et al. Early embryonic lethality of H ferritin gene deletion in mice. J Biol Chem 2000; 275:3021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/22\">",
"      Ferreira C, Santambrogio P, Martin ME, et al. H ferritin knockout mice: a model of hyperferritinemia in the absence of iron overload. Blood 2001; 98:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/23\">",
"      Vanoaica L, Darshan D, Richman L, et al. Intestinal ferritin H is required for an accurate control of iron absorption. Cell Metab 2010; 12:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/24\">",
"      Vaisman B, Meyron-Holtz EG, Fibach E, et al. Ferritin expression in maturing normal human erythroid precursors. Br J Haematol 2000; 110:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/25\">",
"      Finch CA, Bellotti V, Stray S, et al. Plasma ferritin determination as a diagnostic tool. West J Med 1986; 145:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/26\">",
"      Levi S, Arosio P. Mitochondrial ferritin. Int J Biochem Cell Biol 2004; 36:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/27\">",
"      Napier I, Ponka P, Richardson DR. Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood 2005; 105:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/28\">",
"      Ponka P, Beaumont C, Richardson DR. Function and regulation of transferrin and ferritin. Semin Hematol 1998; 35:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/29\">",
"      Salahudeen AA, Thompson JW, Ruiz JC, et al. An E3 ligase possessing an iron-responsive hemerythrin domain is a regulator of iron homeostasis. Science 2009; 326:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/30\">",
"      Vashisht AA, Zumbrennen KB, Huang X, et al. Control of iron homeostasis by an iron-regulated ubiquitin ligase. Science 2009; 326:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/31\">",
"      Theil EC. The IRE (iron regulatory element) family: structures which regulate mRNA translation or stability. Biofactors 1993; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/32\">",
"      Dix DJ, Lin PN, Kimata Y, Theil EC. The iron regulatory region of ferritin mRNA is also a positive control element for iron-independent translation. Biochemistry 1992; 31:2818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/33\">",
"      LaVaute T, Smith S, Cooperman S, et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 2001; 27:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/34\">",
"      Cooperman SS, Meyron-Holtz EG, Olivierre-Wilson H, et al. Microcytic anemia, erythropoietic protoporphyria, and neurodegeneration in mice with targeted deletion of iron-regulatory protein 2. Blood 2005; 106:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/35\">",
"      Zhang AS, Xiong S, Tsukamoto H, Enns CA. Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is expressed predominantly in hepatocytes. Blood 2004; 103:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/36\">",
"      Zhou XY, Tomatsu S, Fleming RE, et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci U S A 1998; 95:2492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/37\">",
"      Vuji Spasi M, Kiss J, Herrmann T, et al. Hfe acts in hepatocytes to prevent hemochromatosis. Cell Metab 2008; 7:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/38\">",
"      Vujic Spasic M, Kiss J, Herrmann T, et al. Physiologic systemic iron metabolism in mice deficient for duodenal Hfe. Blood 2007; 109:4511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/39\">",
"      Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003; 361:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/40\">",
"      Gehrke SG, Kulaksiz H, Herrmann T, et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood 2003; 102:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/41\">",
"      Piperno A, Girelli D, Nemeth E, et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood 2007; 110:4096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/42\">",
"      Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 2006; 281:28494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/43\">",
"      Chen J, Chloupkov&aacute; M, Gao J, et al. HFE modulates transferrin receptor 2 levels in hepatoma cells via interactions that differ from transferrin receptor 1-HFE interactions. J Biol Chem 2007; 282:36862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/44\">",
"      Wallace DF, Summerville L, Crampton EM, et al. Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload. Hepatology 2009; 50:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/45\">",
"      Kawabata H, Yang R, Hirama T, et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 1999; 274:20826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/46\">",
"      Robb A, Wessling-Resnick M. Regulation of transferrin receptor 2 protein levels by transferrin. Blood 2004; 104:4294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/47\">",
"      Johnson MB, Enns CA. Diferric transferrin regulates transferrin receptor 2 protein stability. Blood 2004; 104:4287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/48\">",
"      Johnson MB, Chen J, Murchison N, et al. Transferrin receptor 2: evidence for ligand-induced stabilization and redirection to a recycling pathway. Mol Biol Cell 2007; 18:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/49\">",
"      Forejtnikov&agrave; H, Vieillevoye M, Zermati Y, et al. Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood 2010; 116:5357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/50\">",
"      Wallace DF, Summerville L, Subramaniam VN. Targeted disruption of the hepatic transferrin receptor 2 gene in mice leads to iron overload. Gastroenterology 2007; 132:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/51\">",
"      Roetto A, Di Cunto F, Pellegrino RM, et al. Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues. Blood 2010; 115:3382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/52\">",
"      Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/53\">",
"      Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 2005; 106:2884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/54\">",
"      Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006; 38:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/55\">",
"      Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008; 111:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/56\">",
"      Brasse-Lagnel C, Poli M, Lesueur C, et al. Immunoassay for human serum hemojuvelin. Haematologica 2010; 95:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/57\">",
"      Kautz L, Nemeth E. Novel tools for the evaluation of iron metabolism. Haematologica 2010; 95:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/58\">",
"      Gunshin H, Mackenzie B, Berger UV, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/59\">",
"      Fleming MD, Trenor CC 3rd, Su MA, et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997; 16:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/60\">",
"      Canonne-Hergaux F, Gruenheid S, Ponka P, Gros P. Cellular and subcellular localization of the Nramp2 iron transporter in the intestinal brush border and regulation by dietary iron. Blood 1999; 93:4406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/61\">",
"      Mastrogiannaki M, Matak P, Keith B, et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest 2009; 119:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/62\">",
"      Mims MP, Guan Y, Pospisilova D, et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 2005; 105:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/63\">",
"      Iolascon A, d'Apolito M, Servedio V, et al. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood 2006; 107:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/64\">",
"      Beaumont C, Delaunay J, Hetet G, et al. Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload. Blood 2006; 107:4168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/65\">",
"      Iolascon A, De Falco L. Mutations in the gene encoding DMT1: clinical presentation and treatment. Semin Hematol 2009; 46:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/66\">",
"      Barrios M, Moreno-Carralero MI, Cuadrado-Grande N, et al. The homozygous mutation G75R in the human SLC11A2 gene leads to microcytic anaemia and iron overload. Br J Haematol 2012; 157:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/67\">",
"      McKie AT, Barrow D, Latunde-Dada GO, et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 2001; 291:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/68\">",
"      Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/69\">",
"      Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000; 275:19906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/70\">",
"      Donovan A, Lima CA, Pinkus JL, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005; 1:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/71\">",
"      Bastin J, Drakesmith H, Rees M, et al. Localisation of proteins of iron metabolism in the human placenta and liver. Br J Haematol 2006; 134:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/72\">",
"      Chen H, Su T, Attieh ZK, et al. Systemic regulation of Hephaestin and Ireg1 revealed in studies of genetic and nutritional iron deficiency. Blood 2003; 102:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/73\">",
"      Delaby C, Pilard N, Gon&ccedil;alves AS, et al. Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood 2005; 106:3979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/74\">",
"      Zhang DL, Hughes RM, Ollivierre-Wilson H, et al. A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression. Cell Metab 2009; 9:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/75\">",
"      Keel SB, Abkowitz JL. The microcytic red cell and the anemia of inflammation. N Engl J Med 2009; 361:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/76\">",
"      Zhang DL, Senecal T, Ghosh MC, et al. Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblasts. Blood 2011; 118:2868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/77\">",
"      Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/78\">",
"      Rivera S, Nemeth E, Gabayan V, et al. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 2005; 106:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/79\">",
"      Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001; 28:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/80\">",
"      Pietrangelo A, Montosi G, Totaro A, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999; 341:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/81\">",
"      Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/82\">",
"      Vulpe CD, Kuo YM, Murphy TL, et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 1999; 21:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/83\">",
"      Quigley JG, Yang Z, Worthington MT, et al. Identification of a human heme exporter that is essential for erythropoiesis. Cell 2004; 118:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/84\">",
"      Keel SB, Doty RT, Yang Z, et al. A heme export protein is required for red blood cell differentiation and iron homeostasis. Science 2008; 319:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/85\">",
"      Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/86\">",
"      Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276:7811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/87\">",
"      Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001; 98:8780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/88\">",
"      Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/89\">",
"      Maisetta G, Petruzzelli R, Brancatisano FL, et al. Antimicrobial activity of human hepcidin 20 and 25 against clinically relevant bacterial strains: effect of copper and acidic pH. Peptides 2010; 31:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/90\">",
"      Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012; 338:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/91\">",
"      Lesbordes-Brion JC, Viatte L, Bennoun M, et al. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood 2006; 108:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/92\">",
"      Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 2002; 99:4596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/93\">",
"      Roy CN, Mak HH, Akpan I, et al. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 2007; 109:4038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/94\">",
"      Nicolas G, Viatte L, Lou DQ, et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003; 34:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/95\">",
"      Viatte L, Nicolas G, Lou DQ, et al. Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. Blood 2006; 107:2952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/96\">",
"      Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in &beta;-thalassemic mice. J Clin Invest 2010; 120:4466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/97\">",
"      Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/98\">",
"      Weizer-Stern O, Adamsky K, Margalit O, et al. Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53. Br J Haematol 2007; 138:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/99\">",
"      Pinto JP, Ribeiro S, Pontes H, et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood 2008; 111:5727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/100\">",
"      Huang H, Constante M, Layoun A, Santos MM. Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli. Blood 2009; 113:3593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/101\">",
"      Robach P, Recalcati S, Girelli D, et al. Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood 2009; 113:6707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/102\">",
"      Piperno A, Galimberti S, Mariani R, et al. Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood 2011; 117:2953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/103\">",
"      Fraenkel PG, Gibert Y, Holzheimer JL, et al. Transferrin-a modulates hepcidin expression in zebrafish embryos. Blood 2009; 113:2843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/104\">",
"      Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood 2008; 112:4292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/105\">",
"      Finkenstedt A, Bianchi P, Theurl I, et al. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol 2009; 144:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/106\">",
"      Grebenchtchikov N, Geurts-Moespot AJ, Kroot JJ, et al. High-sensitive radioimmunoassay for human serum hepcidin. Br J Haematol 2009; 146:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/107\">",
"      Girelli D, Pasino M, Goodnough JB, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol 2009; 51:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/108\">",
"      Kroot JJ, Kemna EH, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009; 94:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/109\">",
"      Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011; 117:e218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/110\">",
"      Traglia M, Girelli D, Biino G, et al. Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet 2011; 48:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/111\">",
"      Bayele HK, Srai SK. Genetic variation in hepcidin expression and its implications for phenotypic differences in iron metabolism. Haematologica 2009; 94:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/112\">",
"      Peslova G, Petrak J, Kuzelova K, et al. Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood 2009; 113:6225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/113\">",
"      Laftah AH, Ramesh B, Simpson RJ, et al. Effect of hepcidin on intestinal iron absorption in mice. Blood 2004; 103:3940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/114\">",
"      Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/115\">",
"      Truksa J, Peng H, Lee P, Beutler E. Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. Br J Haematol 2007; 139:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/116\">",
"      Camaschella C. BMP6 orchestrates iron metabolism. Nat Genet 2009; 41:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/117\">",
"      Finberg KE. Regulation of systemic iron homeostasis. Curr Opin Hematol 2013; 20:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/118\">",
"      Meynard D, Kautz L, Darnaud V, et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009; 41:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/119\">",
"      Kautz L, Besson-Fournier C, Meynard D, et al. Iron overload induces BMP6 expression in the liver but not in the duodenum. Haematologica 2011; 96:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/120\">",
"      Frazer DM, Wilkins SJ, Becker EM, et al. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology 2002; 123:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/121\">",
"      Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/122\">",
"      Lin L, Valore EV, Nemeth E, et al. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood 2007; 110:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/123\">",
"      Muckenthaler M, Roy CN, Custodio AO, et al. Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat Genet 2003; 34:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/124\">",
"      Frazer DM, Inglis HR, Wilkins SJ, et al. Delayed hepcidin response explains the lag period in iron absorption following a stimulus to increase erythropoiesis. Gut 2004; 53:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/125\">",
"      Weinstein DA, Roy CN, Fleming MD, et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002; 100:3776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/126\">",
"      Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010; 115:3616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/127\">",
"      Nemeth E, Roetto A, Garozzo G, et al. Hepcidin is decreased in TFR2 hemochromatosis. Blood 2005; 105:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/128\">",
"      Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 2005; 106:3710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/129\">",
"      De Domenico I, Zhang TY, Koening CL, et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest 2010; 120:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/130\">",
"      Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011; 117:4425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/131\">",
"      Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005; 2:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/132\">",
"      Corradini E, Schmidt PJ, Meynard D, et al. BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology 2010; 139:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/133\">",
"      Truksa J, Gelbart T, Peng H, et al. Suppression of the hepcidin-encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase-2/TMPRSS6. Br J Haematol 2009; 147:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/134\">",
"      Silvestri L, Pagani A, Nai A, et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008; 8:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/135\">",
"      Finberg KE. Iron-refractory iron deficiency anemia. Semin Hematol 2009; 46:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/136\">",
"      Finberg KE, Whittlesey RL, Fleming MD, Andrews NC. Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood 2010; 115:3817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/137\">",
"      Chambers JC, Zhang W, Li Y, et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 2009; 41:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/138\">",
"      Ganesh SK, Zakai NA, van Rooij FJ, et al. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet 2009; 41:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/139\">",
"      Soranzo N, Spector TD, Mangino M, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 2009; 41:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/140\">",
"      Tanaka T, Roy CN, Yao W, et al. A genome-wide association analysis of serum iron concentrations. Blood 2010; 115:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/141\">",
"      Nai A, Pagani A, Silvestri L, et al. TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood 2011; 118:4459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/142\">",
"      Delbini P, Vaja V, Graziadei G, et al. Genetic variability of TMPRSS6 and its association with iron deficiency anaemia. Br J Haematol 2010; 151:281&ndash;4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/143\">",
"      Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008; 40:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/144\">",
"      Guillem F, Lawson S, Kannengiesser C, et al. Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency. Blood 2008; 112:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/145\">",
"      Melis MA, Cau M, Congiu R, et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica 2008; 93:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/146\">",
"      Silvestri L, Guillem F, Pagani A, et al. Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia. Blood 2009; 113:5605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/147\">",
"      Edison ES, Athiyarath R, Rajasekar T, et al. A novel splice site mutation c.2278 (-1) G&gt;C in the TMPRSS6 gene causes deletion of the substrate binding site of the serine protease resulting in refractory iron deficiency anaemia. Br J Haematol 2009; 147:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/148\">",
"      Nai A, Pagani A, Silvestri L, Camaschella C. Increased susceptibility to iron deficiency of Tmprss6-haploinsufficient mice. Blood 2010; 116:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/149\">",
"      Shayeghi M, Latunde-Dada GO, Oakhill JS, et al. Identification of an intestinal heme transporter. Cell 2005; 122:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/150\">",
"      Hallberg L, Brune M, Rossander L. Effect of ascorbic acid on iron absorption from different types of meals. Studies with ascorbic-acid-rich foods and synthetic ascorbic acid given in different amounts with different meals. Hum Nutr Appl Nutr 1986; 40:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/151\">",
"      Disler PB, Lynch SR, Charlton RW, et al. The effect of tea on iron absorption. Gut 1975; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/152\">",
"      Hallberg L, Rossander L, Sk&aring;nberg AB. Phytates and the inhibitory effect of bran on iron absorption in man. Am J Clin Nutr 1987; 45:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/153\">",
"      Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006; 127:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/154\">",
"      Conrad ME, Umbreit JN. Pathways of iron absorption. Blood Cells Mol Dis 2002; 29:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/155\">",
"      Shah YM, Matsubara T, Ito S, et al. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab 2009; 9:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/156\">",
"      Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol 2010; 17:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/157\">",
"      De Domenico I, McVey Ward D, Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol 2008; 9:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/158\">",
"      Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell 2010; 142:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/159\">",
"      Prentice AM, Doherty CP, Abrams SA, et al. Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood 2012; 119:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/160\">",
"      Andrews NC, Levy JE. Iron is hot: an update on the pathophysiology of hemochromatosis. Blood 1998; 92:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/161\">",
"      Gitlin JD. Aceruloplasminemia. Pediatr Res 1998; 44:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/37/21082/abstract/162\">",
"      Bosio S, De Gobbi M, Roetto A, et al. Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood 2002; 100:2246.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7105 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21082=[""].join("\n");
var outline_f20_37_21082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3572599\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15257196\">",
"      ROLE OF SPECIFIC PROTEINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transferrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Transferrin saturation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transferrin receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ferritin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Iron regulatory proteins and iron-responsive element binding protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HFE protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1230249\">",
"      Transferrin receptor 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1229645\">",
"      Hemojuvelin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Duodenal iron transporter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Duodenal cytochrome b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Iron exporters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ferroportin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hephaestin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Heme exporter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hepcidin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1230379\">",
"      - Iron sensing and signaling pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      The TMPRSS6 gene and matriptase-2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Iron-refractory iron deficiency anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      REGULATION OF IRON BALANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intestinal iron absorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Regulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Iron loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Iron release from macrophages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3572599\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7105\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7105|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/36/4672\" title=\"figure 1\">",
"      Regulation ferritin and TfR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/11/39088\" title=\"figure 2\">",
"      Ferroportin hepcidin function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/56/1927\" title=\"figure 3\">",
"      Hepcidin regulatory pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/1/36895\" title=\"figure 4\">",
"      Overview of iron homeostasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/50/22318\" title=\"figure 5\">",
"      Control of iron absorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7105|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/5/26715\" title=\"table 1\">",
"      Iron bioavailability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/22/15723\" title=\"table 2\">",
"      Storage iron pool",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14379\" title=\"table 3\">",
"      Assessing menstrual blood loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_37_21083="Diagnosis gonadotroph adenoma";
var content_f20_37_21083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hormonal criteria for the diagnosis of gonadotroph adenomas* (any one or combination of the following)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Men",
"       </td>",
"       <td class=\"subtitle1\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Supranormal basal serum concentrations",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         FSH",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         &alpha;, LH&beta;, or FSH&beta; subunits",
"        </p>",
"        LH and testosterone",
"       </td>",
"       <td>",
"        <p>",
"         FSH but not LH",
"        </p>",
"        Any subunit relative to intact FSH and LH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Supranormal response to TRH",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         FSH",
"        </p>",
"        <p>",
"         LH",
"        </p>",
"        LH&beta; (most common)",
"       </td>",
"       <td>",
"        <p>",
"         FSH",
"        </p>",
"        <p>",
"         LH",
"        </p>",
"        LH&beta; (most common)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Assuming the patient has a sellar mass.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Assuming the patient does not have a history of primary hypogonadism.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21083=[""].join("\n");
var outline_f20_37_21083=null;
var title_f20_37_21084="When to examine CSF in syphilis";
var content_f20_37_21084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for cerebrospinal fluid examination in patients with reactive syphilis serologic tests",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        1. Signs or symptoms of neurosyphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Weakness, pain, paresthesias, sensory changes in the legs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Hyperactive deep tendon reflexes (later, absent DTRs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. Loss of vibratory and position sense in the legs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. Broad-based, stamping gait",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E. Fecal or urinary incontinence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        F. Confusion, psychotic behavior, dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        2. Signs or symptoms of ocular syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Chorioretinitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Acute optic neuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. Optic atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. Pupillary abnormalities (small, fixed pupils that do not react to light)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        3. Evidence of active tertiary syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Cardiovascular syphilis (aortic aneurysm, aortic regurgitation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Late benign syphilis (gummatous syphilis) - protean manifestations, but most frequently involving bones, skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        4. Treatment failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        A. In primary and secondary syphilis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Failure of non-treponemal test titer to decline 4-fold after six months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Failure of non-treponemal test titer to decline 8-fold after twelve months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        B. In early latent syphilis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Failure of non-treponemal test titer to decline 4-fold after twelve months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        5. HIV-infected patients with late latent syphilis or latent syphilis of unknown duration",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from the 2010 Guidelines for Treatment of Sexually Transmitted Diseases, Centers for Disease Control and Prevention, MMWR Recommendations and Reports December 17, 2010. Vol 59&nbsp; No. RR-12.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21084=[""].join("\n");
var outline_f20_37_21084=null;
var title_f20_37_21085="Anaerobic threshold";
var content_f20_37_21085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    V-slope method for determining anaerobic threshold",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 280px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Carbon dioxide output (VCO2) is plotted as a function of oxygen uptake (VO2). The intersection of the two regression lines indicates the anaerobic threshold.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21085=[""].join("\n");
var outline_f20_37_21085=null;
var title_f20_37_21086="Literacy by insurance";
var content_f20_37_21086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Average health literacy scores of adults, by type of health insurance coverage: 2003",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 453px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adults are defined as people 16 years of age and older living in households. Adults who could not be interviewed because of language spoken or cognitive or mental disabilities (3 percent in 2003) are excluded from this figure. Adults who reported they had more than one type of health insurance are included in each applicable category in this figure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Accessed at: National Center for Education Statistics. file://nces.ed.gov/naal/health_results.asp. US Department of Education, Institute of Education Sciences, National Center for Education Statistics, 2003 National Assessment of Adult Literacy.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21086=[""].join("\n");
var outline_f20_37_21086=null;
var title_f20_37_21087="ACE inhibitor advanced HF";
var content_f20_37_21087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62325%7ECARD%2F70015%7ECARD%2F75136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62325%7ECARD%2F70015%7ECARD%2F75136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACE inhibitor improves survival in advanced HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 242px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Decreased mortality in patients with advanced NYHA class III or IV heart failure after treatment with enalapril compared to placebo (p = 0.003).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The CONSENSUS Trial Study Group, N Engl J Med 1987; 316:1429.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACE inhibitor improves survival in moderate HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 246px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enalapril, compared to placebo, decreases patient mortality in NYHA class II and III heart failure (p = 0.0036).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The SOLVD Investigators, N Engl J Med 1991; 325:293.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enalapril improves outcome in asymptomatic LV dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 233px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the SOLVD prevention trial of 4228 patients (83 percent post-MI) with asymptomatic left ventricular dysfunction, prophylactic administration of enalapril reduced the probability of death or heart failure (p &lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The SOLVD Investigators. N Engl J Med 1992; 327:685.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_37_21087=[""].join("\n");
var outline_f20_37_21087=null;
